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Viruses replicating in the respiratory tract (RT) trigger a wide range of cytokines 
and chemokines that have antiviral and pro-inflammatory features, instigating an 
efficient virus- specific B and T cell response that aids in virus- clearance. The majority 
of antibody secreting cells (ASCs) localizing in the upper RT secrete IgA that can 
effectively neutralize viruses. In addition, elements of B cell memory are generated that 
can provide protection from re-infection. Studies examining these aspects, following 
murine gammaherpesvirus 68 (MHV-68) infection comprise chapter 2 of the dissertation 
work. Our studies demonstrate that following MHV-68 infection, unlike influenza 
infection, resulted in a generalized deficiency of virus-specific IgA induction and 
deficient B cell memory establishment in the respiratory tract. Our studies indicate that 
features of virus- replication in the RT regulate these aspects of B cell response. These 
studies lead to the speculation that these features of B cell response may represent an 
evolutionary adaptation of viruses that establish long-term latency and are transmitted 
periodically after reactivation and shedding in secretions. 
Following cognate interactions with CD4+ T cells, the B cells undergo 
proliferation, isotype-switching and differentiate towards extrafollicular (low affinity, 
rapid) or towards germinal center pathway (high affinity). It is not clear what factors 
regulate these pathways of B cell differentiation, especially in the context of virus 
infection in the RT. Studies examining these aspects following influenza infection 
comprise chapter 3 of the dissertation work. Our studies establish a model for the 
investigation of host and viral factors that modulate the quality and effectiveness of the 
B cell response to influenza infection. The findings indicate that the quality/nature of the 
extrafollicular B cell response depends on the nature of the infecting virus. We present 
evidence that this pathway of rapid antiviral antibody production relates to the 
production of non-specifically acting factors in the lung and correlates with the cytokine 
profile of virus-specific CD4+T cells. 
In summary, the current dissertation findings point to an influence of virus and 
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Background and Overview 
 
Overview of the chapter 
The respiratory tract (RT) is susceptible to infection by a wide range of 
pathogens, and the ensuing innate and adaptive immune system mechanisms control 
the pathogen spread and limit damage to the RT. Understanding immune mechanisms 
are important for developing effective vaccines. This chapter begins with a review of 
literature associated with our current understanding of mucosal B cell response in the 
RT, focusing on aspects relevant to the current dissertation work. Briefly, the current 
understanding of acquisition of antigen by B cells are discussed, followed by discussion 
of mechanisms regulating extra follicular and germinal center B cell differentiation 
pathways. Our current understanding of characteristics and trafficking pattern of 
memory B cells and plasma cells are discussed. This is followed by a review of T- cell 
dependent isotype-switching processes in the B cells, with an emphasis on IgA class-
switching. The anatomy of RT is discussed, with emphasis on nasal associated 
lymphoid tissue (NALT). This is followed by an introduction to the models of respiratory 
viruses used in the current dissertation work; a murine gammaherpesvirus 68 (MHV-68) 
and influenza A viruses in order to address questions related to the B cell response. 
The genome features, pathogenesis, immune responses (covering innate, T cell-
mediated immunity (CD4+ T cells, CD8+T cells), B cell-mediated immunity) and current 
vaccine scenario to these respiratory viruses are discussed. The last part of this chapter 
focuses on conclusions emphasizing some of the questions open in the field, with the 
directions taken up by the current dissertation work to answer these questions.         
Antigen acquisition by B cells 
Antigen acquisition by B cells is important for dictating antibody response, 




There are multiple modes for encounter of antigens with follicular B cells [1]. 
Particulate antigens, such as viral particles and immune complexes gain access to the 
lymph node through the afferent lymphatics. The lymph fluid initially passes through the 
sub capsular sinus (SCS) before entering medullary sinus. These antigens gain access 
to the SCS macrophages present in this area, that are geographically situated over the 
B cell follicles. These macrophages are in contact with B cells, requiring B-cells derived 
α1β1 for their development and maintenance [2]. Most importantly, virus particles can 
be captured by these macrophages and also be displayed to B cells through their 
follicular tail processes [3-4]. Extensive studies, summarized in [1] have revealed 
receptors involved in capture of antigen by SCS macrophages. For example, capture of 
UV-inactivated influenza virus is dependent on the receptor, mannose-binding lectin [5]. 
Following exposure to antigen, the B cells accumulate in the SCS region, followed by 
CCR7 up regulation and migration to the T-cell zone [3-4]. Several pathogens directly 
target and infect SCS macrophages resulting in the production of IFNα/β [6], stimulating 
antibody production by B cells [7].  
Alternatively, antigen bound by non-cognate B cells can transfer antigen to 
follicular dendritic cells (FDCs), which then provide antigen to cognate B cells. 
Opsonized antigens are displayed by FDCs, playing an important role in generation of 
antibody response. FDCs have the ability to display antigen for long periods of time and 
cognate B cells can capture antigen from FDCs [8]. Lymph node lymphatic endothelial 
cells can also endocytose viruses and are potentially another candidate for making 
antigen directly accessible to B cells [4]. In contrast, soluble antigens can also directly 
gain access to the B cell follicle, through the conduits. Large antigens too large to enter 
the lymphatic vessels can be presented by DCs to B cells, as evidenced by presence of 
DCs in SCS and also in the B cell follicles [9]. In the upper RT, antigens can be directly 
sampled by M cells present in the epithelium overlying NALT [10]. DCs and 
macrophages are present in the NALT underlying M cells [11], and therefore, have 




Regulation of B cell differentiation 
Following binding of antigen, B cells receive T cell help in the T-B cell border. 
This is followed by proliferation of B cells in the follicles, and some of the cells migrate 
to the extrafollicular areas in the lymph node medullary cords, becoming extrafollicular 
or short-lived plasma cells, secreting rapid, low-affinity antibodies (Abs). Other B cells in 
the follicle differentiate into germinal center (GC) B cells, secreting high affinity Abs [12]. 
Through GC pathway of B cell differentiation, long-lived plasma cells (localizing in the 
bone marrow; BM) and memory B cells (BMem). Factors influencing these pathways of B 
cell differentiation are still unclear. B cells with a strong B cell receptor (BCR) affinity to 
the antigen take up extrafollicular pathway of differentiation [13]. In contrast, another 
study demonstrated that BCR affinity is not the decisive factor, and generates both 
extrafollicular and GC B cells [14-15]. Interestingly, same clones of B cells can be 
present at both sites [16]. Quality of T-cell help is also an important determinant. T cell 
independent responses favor stronger extrafollicular B cell response compared to GC. 
Toll- like receptors (TLR) signals can substitute for T-cell help, stimulating extrafollicular 
B cell response, but is not sufficient for GC sustenance [17]. Both extrafollicular and GC  
B cell responses  are T cell dependent and in the T-B cell border, the extrafollicular B 
cell response may be integrin dependent, while GC B cell response may be additionally, 
SAP dependent [18]. Transcriptional repressors play a major role in the decision making 
early, with Bcl-6 up regulation associated with GC B cells, while Blimp-1 up regulation is 
associated with extrafollicular plasma cells [19]. GC B cell responses up regulate 
interferon regulatory factor 8 (IRF-8) that induces Bcl6, while extrafollicular B cells up 
regulate IRF-4 that induces Blimp-1 [20]. EBI-2 (G-protein coupled receptor) up 
regulation favors localization of B cells to extrafollicular sites, while Bcl-6 mediated 
down regulation of EBI-2 favors localization in the follicles towards GC responses [21-
22]. It is largely still unclear what mechanisms control the decision-making, especially in 




Follicular-helper T cells (Tfh) are one of the important players in regulating GC 
responses and interestingly, B cells are also important for Tfh formation. CD40L 
signaling from Tfh cells may also be important for GC maintenance [12]. IL-21 produced 
by Tfh cells is also important for GC responses. IL-21 can act in two ways; by inducing 
formation of Tfh cells [23] and by directly acting on B cells [24-25]. IL-21 is important for 
IgG1 class switching, proliferation, maintenance and affinity maturation of GC B cells 
and enhances Bcl-6 expression. Other cytokines, including IL-4 [26]and IL-17 [27] are 
important for attaining normal GC numbers and maintenance. BCR signaling and FDCs 
derived integrin and survival signals are also important determinants for formation and 
maintenance of GCs [12].  
B cells trafficking pattern in the respiratory tract 
 Naive B cells migrate to peripheral lymph nodes in search of antigen and this 
process is less dependent on CCR7-CCL19/CCL21 axis, but more dependent on 
CXCR4-CXCL12 and CXCR5-CXCL13 axes. Following exposure to antigen activated B 
cells increase CCR7 expression, migrating to the T-cell zone, in response to the 
ligands, CCL19, CCL21 [28-29]. Trafficking to extralymphoid tissues involves down 
regulation of these receptors and upregulation of other chemokine receptors that aid in 
migration to inflammatory and mucosal sites. The trafficking of IgA and IgG ASCs are 
differentially regulated. The IgA antibody secreting cells (ASCs) have trafficking patterns 
related to the site of induction. For example, IgA ASCs generated in the upper RT 
preferentially populate the salivary glands and RT, and decreased trafficking to the gut. 
In contrast, IgG ASCs preferentially traffic to lymphoid tissue and non-mucosal sites of 
chronic inflammation [30]. The BM is a site for localization of long-lived plasma cells 
(more IgG and IgM ASCs, and relatively few IgA ASCs) that contribute to the circulating 
Abs in the serum. IgG and IgA ASCs localize in the BM using the CXCR4-CXCL12 axis 
[31]. Other axes working in the BM includes CXCR6-CXCL16 and CCR10-CCL28 [30]. 
Interestingly, CXCL12 is expressed in the epithelium of mucosal tissues [32] and 
perhaps a parallel system in the RT could contribute to the localization of CXCR4+ASCs 




IgG ASCs migrate to inflammatory sites (for example, lung, following intranasal 
infection) under the influence of CXCR3-CXCL9/CXCL10 axis [33]. IgA ASCs 
expressing CCR10 respond to the ligand CCL28 produced by epithelial cells associated 
with mucosal tissues of RT and gut [34-35]. In contrast, very few IgG or IgM ASCs are 
CCR10+ [30]. Following intranasal route of immunization, there is up regulation of 
CCR10 and α4β1 on IgA ASCs which traffic to the RT in response to their respective 
ligands, VCAM1 and CCL28 [30]. IgG ASCs expressing low levels of CCR10, α4β1 and 
CXCR3 may be programmed to enter the RT [30]. BMem are constantly re-circulating 
through secondary lymphoid tissues and respond to CCR7, CXCR5, CCR6 and CXCR4 
associated axes [30, 36]. CCR10 is not expressed by BMem [37] and it is not clear what 
mechanisms govern their migration to the RT. In contrast, CCR9 expression is 
detectable on BMem [33], helping them to circulate through mucosal sites associated with 
the gut.      
Regulation of B cells in the RT  
GC reactions are considered central to the generation of BMem and long-lived 
plasma cells. For example, SAP deficient mice develop short-lived ASCs, but fail to 
develop GCs, BMem and long-lived ASCs, emphasizing the importance of signals from T 
cells in these processes [38-39]. Other signals including over expression of Bcl-2 in B 
cells lead to increase in BMem frequencies and ASCs in the BM [40-41]. Reduced IL-21 
in the microenvironment contributes to increased BMem frequencies, but reduced 
frequencies of ASCs localizing in BM [24-25]. SWAP-70 expression is up regulated in 
GC B cells, and is down regulated in plasma cells as indicated by studies associated 
with SWAP-70 deficient mice [42]. Interestingly, ASCs localizing in BM and BMem are 
generated, although at reduced frequencies, in the absence of GCs [43-44]. Several 
mechanisms control maintenance of BMem [41]. For example, BAFF is important for 
survival and maintenance of B cells [45] . Spleen is a major repository of IgG BMem cells 
[46] and it is unclear what mechanisms govern the maintenance of these cells in this 
site. Interestingly, in the absence of secondary lymphoid tissues, BMem are still 




Providing survival factors play a major role in maintenance of ASCs in the RT. For 
example, APRIL over expression in tonsils provide survival niches for IgG and IgA 
ASCs [41, 48]. It will be interesting to examine if such parallel mechanisms exist in 
oNALT that are considered equivalents of tonsils. 
Regulation of class-switching in B cells       
During the antigen-independent phase of B cell development, the B cells diversify 
the antibody repertoire by a non-homologous end-joining process [49]. Following 
rearrangement of light chains by VL-JL recombination and heavy chains by VHDJH 
recombination, the mature B cells are IgM+IgD+. During the antigen-dependent phase of 
B cell development, somatic hypermutation, affinity maturation and class-switch 
recombination occurs, resulting in the generation of high-affinity B cells [49]. The 
process of class switching in IgM+IgD+ B cells (in the IgH - constant region) is important 
in the generation of different isotypes of antibodies: IgG1, IgG2b, IgG2c/IgG2a, IgG3 
and IgA. These class-switched B cells have similar antigen specificity as the precursor 
cells, but different effector functions [50]. Cytokines from CD4+ T cells involved in 
cognate interactions with B cells are important in the process of class switching. For 
example, IgG1 class switching is mediated by IL-4 [51-52], secreted by Th2 cells, while 
IgG2c class switching is mediated by IFN-γ [53] secreted by Th1 cells. In addition, Th1 
cells can inhibit Th2 cells. Although several mechanisms regulate the differentiation of 
Th1 Vs Th2 cells, it is still unclear how these processes are regulated, especially in the 
context of a virus infection in the RT.  
Regulation of IgA class switching 
Class-switching to IgA results in generation of both secreted IgA (sIgA) as well as 
membrane bound IgA. The sIgA is present as dimeric and oligomeric forms [54]. The J 
chain is generated by plasma cells and has a dual function [55]. It helps in the 
interaction of IgA monomers and also interacts with polymeric Ig receptor (pIgR), 




forms of complexes that also contain a secretory component generated by cleavage of 
pIgR [57].  
The T-cell dependent IgA class switching is dependent on the cytokine TGFβ1 
and CD40L mediated mechanisms [58]. The process of IgA class-switching is mediated 
by switching Cµ to Cα through switch (S) regions which are G-rich regions [59]. Tolecular 
mechanism for IgA class switching is described in [58]. Briefly, the S region is preceded 
by intronic exons (I) and a promoter (P), for each constant gene. TGFβ1 mediates the 
initiation of Cα gene transcription, resulting in the generation of germline Iα - Sα- Cα 
transcript, from the promoter Pα of Iα exon. This process results in S region to become 
susceptible to the enzyme, activation induced cytidine deaminase (AID). The AID is 
important in generation and repair of dsDNA breaks at Sµ and Sα, also resulting in the 
generation of short half-life, Iα-Cα switch circle transcripts. This is followed by 
recombinatorial events leading to the generation of m-RNAs for secreted IgA and 
membrane IgA [58]. AID expression is induced via NF-κB pathway in B cells via CD40L-
CD40 interaction [58, 60]. Alternatively, it is also likely that CD40L along with cytokines 
such as IL-10, IL-2,IL-4,IL-5 and IL-6 may act on B cells and induce autocrine induction 
of TGFβ1, resulting in IgA class switching [58]. Currently, it is not clear if both these 
mechanisms operate in an in vivo setting. The source of TGFβ1 in the context of virus 
infection in the RT is unclear, although certain T cell subsets can secrete this cytokine 
[58]. Interestingly the IgA class switching effects mediated by TGF-β1 is dependent on 
concentrations, as low concentrations favor class switching, while higher concentrations 
inhibit B cell proliferation and differentiation [61]. In addition, T-cell independent 
mechanisms also regulate IgA class switching, including TLR signaling [62]. In addition, 
BAFF and APRIL are molecules secreted by DCs that can replace the role of CD40L, 
mediating class switching to IgA [63]. 
Characteristics of nasal-associated lymphoid tissue   
The nasal-associated lymphoid tissue (NALT) is comprised of organized-nasal-




(dNALT) [64]. The NALT is considered equivalent to waldeyer’s ring in humans [64-
65].The oNALT is a pair of lymphoid structures present above the palate at the entrance 
of the nasopharyngeal duct and the epithelium has M cells which sample antigens. In 
addition, DCs and CD11b+Ia+ macrophages, along with HEVs and B, T cells-rich areas 
are also present in the oNALT [10]. Interestingly, i.n. administration of reovirus leads to 
generation of GCs in the oNALT [66]. Characterization of CD4+ T cells in the oNALT 
revealed that these T cells were capable of differentiating into either Th1 or Th2 cells 
depending on the kind of antigen exposure [67]. In addition, oNALT is also a site for 
generating both IgA ASCs and IgA BMem [46], secreting high affinity IgA Abs [68] that 
can effectively neutralize viruses in the upper RT. In addition, some studies indicate that 
IgA-secreting cells in cervical lymph nodes (CLN) originate from oNALT [69]. dNALT is 
the diffuse lymphoid tissue lining the nasal passages. Both oNALT and dNALT have 
similar ratios of B and T cells [70]. In contrast, the precursor IgM+B220+ B cells, AID 
expression and IgA switch transcripts are found in the oNALT but are absent in the 
dNALT [71]. Unlike oNALT, where the IgA response wanes down towards the end of 
acute phase of infection, IgA ASCs are found localized in the dNALT over a long period 
of time following infection [46, 72]. The NALT is also a source for IgA Abs in the nasal 
wash, which in the context of influenza infection correlates with virus clearance from 
nose [73].            
Models of respiratory virus infection in the current dissertation work 
Respiratory virus infection model systems in mice provide insights into the 
mechanisms important for the resolution of infection. A couple of RT- associated 
disease models have been described in the current dissertation work; a murine 
gammaherpesvirus 68 (MHV-68) and influenza A viruses. The acute phase of 
pathogenesis, including mechanisms of virus control mediated by CD4+ and CD8+ T 
cells are largely similar between these viruses. The major difference being, that MHV-68 
establishes latency and causes systemic disease, while influenza viruses cause a very 





Murine gammaherpesvirus 68  
Herpesviruses 
The family of herpesviruses is divided into three subfamilies, alpha (α), beta (β) 
and gamma (γ). The α-subfamily includes herpes simplex (HSV-1, HSV-2) and varicella-
zostere virus (VZV), and these viruses have a general tropism for sensory nerve 
ganglia. HSV-1 is associated with cold sores, HSV-2 with genital lesions, and VSV with 
shingles. The β-subfamily includes the human cytomegalovirus (HCMV), human 
herpesvirus (HHV-6, HHV-7) and these viruses have a cellular tropism for monocytes, 
macrophages, lymphocytes and the salivary gland. HCMV is associated with congenital 
defects, and is also a causal agent in nosocomial infections in the immuno-
compromised individuals.  
The γ-subfamily is divided into two genera, Lymphocryptoviridae and 
Rhadinoviridae. The Lymphocryptoviridae genus includes Epstein Barr virus (EBV), and 
the Rhadinoviridae genus includes Kaposi’s sarcoma- associated herpesvirus (KSHV), 
and also other KSHV-like non-human viruses. The lymphocryptoviruses infect only 
primates and humans, whereas the rhadinoviruses infect other mammals too, including 
voles [74-75], mice (Murine gammaherpesvirus 68/ MHV-68 and others), horses (equine 
herpesvirus 2), cows (bovine herpesvirus 4), pigs and primates [76-83] Molecular 
phylogenetic analyses have shown that the γ-herpesviruses are closely related to each 
other, and are very distinct from the α and β herpesviruses [84]. The human γ-
herpesviruses have tropism for B cells, epithelial cells and endothelial cells.  
MHV-68 as a model system to study gammaherpesvirus immunobiology 
The human gammaherpesviruses are species-specific viruses, and as a result, the 
studies have been restricted to clinical aspects of disease. Infection of mice with a 
closely related rodent virus, MHV-68 (Murid herpesvirus 4 (MuHV4) / γ-HV68) offers a 
good small animal model system to study immunological features of human 
gammaherpesvirus infection [85-88]. Based on the genome properties [89], MHV-68 




amenable to genetic modifications to study viral gene functions, related to virus 
replication, latency and reactivation features in the host.  
MHV-68 was originally isolated from Clethrionomys glareolus (bank vole) in 
Slovakia [74] and also replicates well in Apodemus flavicollis (wood mice) [90]. Two 
other herpesviruses, MHV-60 and MHV-72 were isolated from bank voles, and viruses 
MHV-76 and MHV-78 were isolated from wood mice. MHV-Brest was isolated from 
Crocidura russula (Shrew) [91]. In addition, an extensive survey in Slovakia revealed 
the presence of the virus in rodents, fallow deer, wild boar and sheep. Interestingly, 
MHV-68 neutralizing antibodies were identified in a set of employees of the institute of 
virology, Slovak academy of sciences [92].     
Human diseases associated with γ-herpesviruses 
The γ-herpesviruses are known to induce lymphoproliferative diseases and cancer. 
EBV and KSHV are associated with both benign and malignant lymphomas, along with 
those associated with smooth muscle cell and endothelial cell origin. The mechanisms 
behind the tumor induction is unclear, but there are indications that tumorigenesis is 
triggered when viruses infect across-species [80]  or  most commonly in cases of 
immuno-compromised individuals. The magnitude and outcome of infection is also 
influenced by the age of the individual when they acquire the infection. In addition, the 
stage of the life cycle of the virus also plays a critical role in determining the outcome of 
infection.  
For example, EBV infection in young children is asymptomatic, while infection 
acquired during adulthood is associated with infectious mononucleosis (IM) [93]. 
Reactivation of EBV in HIV patients results in oral hairy leukoplakia (OHL) and 
immunoblastic lymphomas and tumors of muscle origin. In young adults with X-linked 
immunodeficiencies, EBV infection results in a severe case of IM, resulting in death. 
During latency stages of EBV infection, the disease may progress to Burkitt’s lymphoma 
(BL) [94-95] and epithelial tumor associated nasopharyngeal carcinoma (NPC). In 




also associated with other diseases such as T-cell lymphomas, gastric carcinomas and 
Hodgkin’s disease. The association of EBV with breast carcinoma and hepatocellular 
carcinoma is not clear.  EBV is also associated with several autoimmune disorders such 
as multiple scelorosis, rheumatoid arthritis, and diabetes.   
KSHV is associated with Kaposi’s sarcoma (KS) [97], primary effusion lymphoma 
(PEL) or body cavity based lymphoma [98],and multicentric Castleman’s disease 
(MCD)[99]  MCD is characterized by lymphadenopathy, fever and splenic infiltration 
[100]. It is also associated with hyper IL-6 production and inflammation. Interestingly, 
PEL and MCD are of B cell origin and KS is of endothelial cell origin. In children, 
primary infection with KSHV is associated with a febrile maculopapular skin rash [101]. 
In case of a primary infection in adults that are immunosuppressed, have bone marrow 
failure, splenomegaly and fever [102]. KSHV may also be transmitted to new hosts by 
organ transplants [103]. KSHV is also associated with sarcoidosis [104], multiple 
myeloma [105] and severe primary pulmonary hypertension [106].     
Genome features of MHV-68 
The complete genome of MHV-68 has been sequenced [89]. The viral genome is a 
linear ds DNA, with 118,823bp of unique sequence, G+C content of 46% and consists 
of multiple copies of 1.2Kb terminal repeat flanking the unique sequence [75]. In 
addition, the genome has a couple of internal repeats called Bam repeats (these 
repeats have a BamHI restriction site) present as 40bp repeats and 100bp repeats. The 
virus encodes 80 gene products, with 21 genes that are herpesvirus family common 
genes. These genes comprise 25% of viral genome. More than 40 genes are 
gammaherpesvirus subfamily common genes, and there are16 unique MHV-68 specific 
genes, designated as M1-M9, M10 a, b, c, M11-M14.  Some of the major MHV-68 
specific gene functions are compiled and listed in Table 1.1. In addition, several of the 
MHV-68 genes are homologous to cellular genes and also to the human 
gammaherpesviruses [107]. The herpesvirus gene expression following infection is 




MHV-68 associated genes falling into these categories have been described, 
based on DNA microarray anaysis, RT PCR analysis, following infection in murine 
epithelial cells [108]. Kinetics of MHV-68 genes following intranasal infection in Balb/c 
mice has revealed that there are differential patterns of viral gene expression in the 
lungs, mediastinal lymph node (MLN) and in the spleen [109].          
MHV-68 pathogenesis 
The natural route of infection of MHV-68 is not known. For other animal 
gammaherpesviruses, the route of infection seems to be through the respiratory tract. In 
addition, viral DNA has been detected in the lungs of captured wood mice, suggesting 
intranasal route of infection and transmission through aerosols as a likely normal route 
of infection and spread [90]. The intranasal (i.n.) route of infection is the most commonly 
used method of inoculation of MHV-68. Oral exposure of MHV-68 to mice resulted in 
replication in the intestinal epithelium, and the virus survived in the acidic gastric 
environment. In addition, MHV-68 spread systemically, and established latency with 
similar kinetics to that of the i.n. route of infection [110]. On the other hand, a recent 
study demonstrated that MHV-68 given orally is poorly infectious [111], suggesting i.n. 
as a possible route of natural infection. The other route of inoculation has been intra-
peritoneal (i.p.) inoculation and this result in seeding virus directly to the spleen. In 
addition, the roles of M2 and M11 are evident only through i.n. infection, and their 
functions are by-passed in the i.p. method of infection [112-113].  
Following i.n. method of infection, the virus replicates efficiently in the respiratory 
tract of mice. Replication patterns of the virus has been studied in great detail using a 
bioluminescence imaging system in whole mouse, using a recombinant MHV-68 
expressing firefly luciferase [114] and also by monitoring the luciferase expression by a 
charge-coupled-device camera scanning [111].   MHV-68 replicates efficiently in both 
the upper and the lower respiratory tract. Following intranasal infection with 104 PFU 
(note: this is the dose that we are using in the majority of our studies), the virus is 




This has been demonstrated by several other studies too [115-116]. Following from 
day’s 7- 10-post infection, the virus can be detected in the draining lymph nodes; 
mediastinal lymph node (MLN) and the cervical lymph nodes (CLN), with a higher 
proportion in the superficial cervical lymph nodes than in the deep cervical lymph nodes. 
By day 10, the virus could also be detected in the spleen [111]. In addition, by day 8, the 
virus was detected in the salivary glands, and by two weeks, in the peritoneum. 
Interestingly, some virus was also detectable 1-2 months post infection in the nose, and 
in the salivary glands, indicating possible virus reactivation sites [114].   
Recently, some of the studies have implicated the role of MHV-68 associated 
factors that affect the virus replication in the respiratory tract.  One of the extensively 
studied factors is the thymidine kinase (TK). Intranasal inoculation of TK deficient 
mutants, resulted in failure to replicate in the nose, but could still replicate efficiently in 
the lungs, as measured by luciferase imaging [117].  Interestingly, the TK deficient 
mutants were undetectable in both the nose and lungs by plaque assay [118], 
highlighting the level of sensitivity of detection by the two methods. In addition, ORF27 
gene product is involved in cell-to-cell spread, and is important during the acute phase 
of infection [119]. Following disruption of ORF61, which encodes for the large subunit of 
ribonucleotide reductase demonstrated defective upper and lower respiratory tract 
infection [120].    
Following infection in the lungs, MHV-68 replicates productively in the alveolar 
epithelial cells, mononuclear cells [116]. It is not clear what cells are targeted in the 
upper respiratory tract, but recent studies using TK mutants highlighted the possibilities 
[117-118]. Specifically, the TK mutant still replicated in B cells, driving their proliferation, 
and therefore raising the speculation that MHV-68 probably does not infect B cells in the 
upper respiratory tract. Interestingly, TK mutants failed to replicate in the macrophages. 
MHV-68 infection in mice results in lung inflammation and bronchiolitis. Interestingly, a 
closely related strain, MHV-76 infection resulted in a more rapid clearance from the 




isolate that has an identical genome to that of MHV-68, except a 9.5Kb region on the 
left end of the unique region is deleted. The 9.5 Kb region has 12 genes; M1, M2, M3, 
M4, and eight vtRNAs. By day 3 post-infection, macrophages infiltrate the lungs, 
followed by CD8 T cells, peaking at day 7.  In addition, there is also a massive increase 
in the number of circulating Vβ4+ CD8 T cells, which is similar to the infectious 
mononucleosis disease [122]. The inflammation is cleared by 14 days post infection, but 
the mononuclear cells are still visible in the lungs up to 30 days post infection [116]. 
MHV-68 replication can also be detected at distant sites, such as the adrenal glands. In 
the lungs, although the virus establishes latency in the B cells, macrophages and 
dendritic cells, but during the long-term, latent virus is found only in the B cells [123]. 
The lung epithelial cells have also shown to be a site of persistence [124].  The virus 
enters the MLN following infection in the lungs, and infects B cells, macrophages and 
dendritic cells. Following infection, the B cells undergo expansion, and there is an 
increase in the number of latently infected B cells [56] (see Figure 1.2).  
The latently infected B cells migrate from the MLN to the spleen by 14 days post-
infection. The latently infected B cells also expand in the spleen, resulting in 
splenomegaly. In the spleen, the latency is established in B cells [59], dendritic cells and 
macrophages [49, 123]. Interestingly, among the B cells, there is a preference for 
latency establishment in activated B cells that are associated with germinal center 
reaction [57] and memory B cells [125] . This feature also syncs with the observations 
associated with EBV [126-127]. In addition, blood also carries latently infected virus 
through isotype-switched B cells [123]. The latently infected B cells also migrate to non-
lymphoid sites such as the vascular endothelial cells [128]. Interestingly, the ability to 
establish latency is independent of the lytic infection [129-130]. This feature is also 
evident in TK deficient mutants that demonstrate attenuated lytic replication, but still can 
establish latency efficiently [118]. Latently infected B cells migrate to the mucosal sites 




Reactivation of virus is important for virus transmission to a new host and also for 
expanding the pool of latently infected cells [131-132].  Several agents, such as phorbol 
esters, sodium butyrate, calcium ionophore, etc, can stimulate the reactivation of latent 
gammaherpesviruses .  In vitro studies with MHV-68 infected B cell lymphoma cell line, 
S11, revealed the importance of RTA (lytic transactivator) in the process of reactivation 
of MHV-68 [133]. Interestingly, administration of LPS and cPG intra-peritoneal to the 
mice that have been infected with MHV-68 intranasally resulted in reactivation of the 
virus in lungs, with increased CD8 T cell responses. In addition, the resulting 
reactivation resulted in increased frequencies of latently infected cells [134]. MyD88 -/- 
mice infected with MHV-68 have a defect in reactivation [135]. Several studies also 
indicate a direct role for NF-κB in MHV-68 reactivation. Specifically, NF-κB activation 
results in establishment of latency [136], whereas down-regulation of NF-κB activation 
results in reactivation of virus [137]. The exact mechanism of reactivation through this 
pathway is unknown. MHV-68 associated genes are also involved in the process of 
reactivation. One of the most important genes is a transcriptional activator 
(RTA)/ORF50. Mutations in RTA result in failure to reactivate and constitutively active 
RTA results in failure to establish latency [138]. Plasma cell differentiation can also 
result in reactivation of virus, and this seems to be modulated by MHV-68 associated 
M2 gene; absence of M2 results in failure to reactivate [139].    
Vaccination strategies  
Peptide and subunit vaccination strategies targeting lytic and latent proteins 
reduce lytic replication and latency, but do not affect long-term latency establishment 
[140-142]. gp150-expressing vaccinia virus immunized mice were protected from 
infectious mononucleosis, but did not affect latency establishment following challenge 
with live virus [132]. Heat- inactivated vaccine reduced lytic replication, but did not 
prevent establishment of long-term latency following challenge with live virus [132]. 
Interestingly, live-attenuated viruses that are deficient in latency establishment are very 




attenuated viruses were created by over expressing RTA, using different strategies 
[138, 143-144] or by deletion of ORF73 [145].      
MHV-68 Immune response 
Innate response 
MHV-68 infection in type I IFNR-/- mice results in an increased mortality and a 
rapid spread to the lymph nodes. In addition, these patterns of pathogenesis were also 
evident in IRF-1 deficient mice [146]. In contrast, following infection of MHV-68 in type II 
IFNR-/- mice, there is severe fibrosis, with an increased pro-inflammatory cytokines. 
Interestingly, the pathology associated with the infection of MHV-68 in type II IFNR-/- 
mice is dependent on CD4+ and CD8+ T cells [114].  MHV-68 infection results in an 
increased production of IFN-γ by T cells [147]. IFN-γ does not play an important role in 
virus control during both acute and latent phases of infection [114, 117]. In addition, 
although there are strain differences, with BALB/c mice infected with MHV-68 
demonstrating increased IFN-γ production in the lungs, as compared to C57/BL6 mice, 
the viral gene expression is similar in both the strains [148]. MHV-68 infection in IFN-γ -
/- mice did not result in IL-4 and IL-5 production [117]. IL-6 is one of the predominating 
cytokines produced following MHV-68 infection [147]. MHV-68 infection in IL-6-/- mice 
does not influence virus replication or latency or the immune response [149]. MHV-68 
infection also induces IL-10 [147], mediated by M2 gene product [150].  MHV-68 
infection in IL-10-/- mice results in increased production of IL-12 ,with increased 
splenomegaly [116]. Along these lines, MHV-68 infection in IL-12-/- mice demonstrated 
increased lytic and latent virus load, with decreased IFN-γ production [116].  
Following MHV-68 infection, there is an increase in expression of chemokines, 
such as RANTES, eotaxin, MIP-1α. MIP-1β, IP-10, MCP-1 in the lungs. There is also an 
increased expression of MCP-1, RANTES, MIP-1α, eotaxin and MCP-1 in the BAL 
[151].  In addition, there is also upregulation of chemokine receptors, such as CCR1, 
CCR2, CCR3, CCR5 and CXCR3 [151-152]. CXCR3-/- mice infected with MHV-68 




chemokine expression observed is similar to the pattern observed following other 
respiratory viruses infection. Interestingly, the chemokines are expressed in the lungs in 
two distinct patterns. The first sets of chemokines are expressed rapidly, while the 
second patterns of chemokines have delayed kinetics, and were expressed up to a 
month post-infection [152].  MHV-68 carries two gene products, M3 and ORF74, which 
modulate the chemokine response. ORF74 encodes a CXCR2 chemokine receptor 
homologue [154], and M3 protein binds CC and CXC chemokines [155]. Although M3 is 
secreted in large amounts in the lung, it has no effect in vivo in modulating the host 
chemokine response [152]. Interestingly, there are also genetic differences in the 
pattern of cytokine and chemokine induction. Overall, the BALB/c mice displayed 
increased cytokine and chemokine induction as compared to the C57BL/6 mice. But, 
this increase did not translate into differences in virus clearance in the lungs and also in 
terms of latency establishment [148].      
T-cell response  
In CD8+ T cell depleted BALB/c mice; following high dose MHV-68 infection, 
there is an increased mortality, with increased virus load [156], which is not observed in 
CD8+T cell deficient C57BL/6 mice . Such host genetic differences are also reflected in 
MHV-68 infected β2-microglobulin deficient mice (lack CD8+ T cells). MHV-68 infected 
β2-microglobulin on a BALB/c background displayed lymphoproliferative disease [157], 
in contrast to the C57BL/6 background that displayed no disease. In contrast to the 
situation following LCMV infection [158], the MHV-68-specific CD8+ T cell response is 
independent of the CD4+ T cell help [159]. Interestingly, in CD4+ T cell depleted 
C57BL/6 mice; a chronic wasting disease is observed [115], and in this scenario, the 
CD8+ T cells are not defective [159]. Not surprisingly, mice depleted with both CD4+ 
and CD8+ T cells resulted in mortality [160]. Therefore, CD8+ T cells play an important 
role in controlling lytic phase of replication but are not effective in controlling long-term 
infection. One possible reason could be the role of MHV-68 encoded CD8+ T cell 
immune evasion gene products, such as K3, expressed during both lytic and latent 




chains [162]. A more recent role for K3 in down-regulating MHC-Class I in migratory and 
lymph node dendritic cells has been identified, an immune evasion strategy that could 
aid in establishment of virus persistence [163]. In addition, M3, a chemokine binding 
protein, can also inhibit CD8+T cell function [164].   
The MHV-68 peptides that are associated with the majority of the CD8+ T cell 
response during the acute and persistent phase of infection have been well-
characterized [165]. The peptide-specific CD8+ T cell response are measured through 
intracellular IFN-γ staining. The kinetics of the CD8+ T cell response is typical of other 
respiratory viruses, such as influenza viruses. Following intranasal infection of MHV-68, 
there is a steady increase in the CD8+ T cell response from day 10 in the MLN and 
spleen, until the end of lytic infection. The MHV-68 specific CD8+ T cells recovered from 
BAL and MLN, spleen display distinct groups of peptide specificity [165-166]. In 
addition, the frequencies of MHV-68 specific memory CD8+ T cell precursors were 
similar to influenza [166].    
An interesting feature of CD8+ T cell response to MHV-68 is the expansion of 
activated Vβ4+ CD8+ T cell population in the peripheral blood and lymphoid tissue 
during the end of acute phase and is detectable up to a month after infection [122, 167].  
This feature is similar to the infectious mononucleosis syndrome induced by EBV in 
humans. The expansion of this population of CD8+ T cells is independent of MHC-class 
I [165], and is dependent on the presence of B cells and CD40L interaction through 
CD4+ T cells [168]. Interestingly, during the mononucleosis state, there is a decrease in 
the activity and the number of CD4+CD25+FoxP3+ cells, indicating a feature of immune 
dysregulation [169].  
Following depletion of CD4+ T cells in B-cell deficient mice, there is increased 
virus titers in lungs during the acute phase of infection, demonstrating direct control of 
virus by CD4+ T cells [170]. The CD4+ T cells control virus in both acute and latent 
phases of infection primarily through IFN-γ production [171]. They also provide help to 




virus directly, but instead function by providing B cell help [173]. CD4+ T cells also play 
a critical role in the development of splenomegaly [174] and also for the expansion of 
Vβ4+ CD8+ T cells [168]. The CD4+ T cells play an important role in controlling latency 
[129, 143, 175] via IFN-γ production [176]. The frequencies of MHV-68 specific CD4+ T 
cell response determined by IFN-γ ELISPOT assay during acute phase of infection 
revealed a steady increase in MLN and spleen.  Interestingly, a CD62L lo and CD44hi 
feature is maintained over long-term [177], which is contrasting to other respiratory 
viruses [178].       
B-cell response 
  B cells through antibody production control persistent MHV-68 infection [179]. 
Passive transfer of both neutralizing and non-neutralizing antibodies control acute virus 
replication primarily through host IgG Fc receptors [180]. The glycoprotein, Gp150 aids 
in epithelial cell infection [181] and interestingly, antibodies against Gp150 do not 
neutralize the virus [182].  Following infection of B cells in vitro with MHV-68, there is an 
increased IL-6 and IgM production, with higher CD69 expression [172]. MHV-68-specific 
B cell response has been well-characterized in the draining lymph nodes, spleen and 
bone-marrow. The analysis revealed an earlier B cell response in the MLN compared to 
other sites. Overall, the response is delayed compared to other respiratory viruses. In 
addition, the B cell response is skewed towards IgG2b and IgG2c response, 
characteristic of a Th1 response. There is also an absence of virus-specific IgA in the 
draining lymph nodes, a feature inconsistent with other respiratory viruses. In addition, 
there is also a substantial component of nonspecific antibody production following MHV-
68 infection, a feature dependent on CD4+ T cells in vivo [183]. The respiratory mucosa 
is a critical site for MHV-68 entry, replication, latency establishment, reactivation and 
transmission, but little is known about the B cell mediated mucosal immunity to the 




Influenza A virus 
Genome and virus replication features 
Influenza viruses are enveloped, negative strand, single-stranded RNA viruses 
and belong to the orthomyxoviridae family. Influenza viruses are classified as types A, B 
and C. Influenza A viruses (IAVs) are the most pathogenic type, infecting humans [184-
185].  
IAVs genome has eight RNA segments, coding for up to 11 proteins. The RNA 
segments include nucleoprotein (NP), viral polymerase complex comprised of PB1, PB2 
and PA proteins. In contrast, proteins matrix protein (M1), hemagglutinin (HA), 
neuraminidase (NA), ion channel protein (M2), non-structural proteins (NS1 and NS2, 
with NS1 being found in virus infected cells) are associated with the surface of virus 
(See Figure 1.3) [184-185]. 
IAVs are subtyped according to the surface antigens HA and NA. So far 16 
subtypes of HA and 9 types of NA have been described in birds. The lung epithelial 
cells of the upper and lower RT are targeted in the mammals [186]. Along with epithelial 
cells, other cells including monocytes, macrophages are infected [187]. Genetic 
variations are common in IAVs and allow efficient escape from the immune system. 
Antigenic drift is characterized by increased point mutations in the virus results in 
generation of a new virus that enables the new virus to evade adaptive immune system 
and antiviral treatments. In contrast, antigenic shift is characterized by genetic re-
assortment in double infected cells resulting in generation of viruses that have altered 
surface structures, compared to the parent strains [186]. 
IAVs binds sialic-acid containing receptors through the HA receptors. The virus is 
endocytosed through clathrin-dependent mechanism. Low pH of 5-6 in the endosomes 
favors fusion of viral and endosome membranes, resulting in the release of 
nucleocapsids into the cytoplasm. These nucleocapsids are then transported into the 




transcription). The viral mRNAs are transported back to the cytoplasm where translation 
occurs and the new set of proteins synthesized is transported back to the nucleus which 
mediates secondary transcription that includes synthesis of complementary RNA 
(cRNAs) and secondary vRNAs. The secondary vRNAs are transcribed into mRNAs 
that are transported into the cytoplasm where translation occurs and synthesis of 
structural proteins occurs. The structural proteins are transported into the nucleus 
where assembly of nucleocapsids occurs. These nucleocapsids are transported into the 
cytoplasm and plasma membrane where budding and release of virus particles occurs. 
(See Figure 1.4) [184-185]    
Influenza virus immune response         
Innate response 
Following i.n. infection of IAVs, the epithelial cells, alveolar macrophages, 
dendritic cells in the RT are exposed to virus particles which recognize the virus through 
pattern-recognition receptors (PRRs). This interaction leads to the induction of cytokines 
and chemokines [188]. The TLR (Toll-like receptors) family is a classic example of 
PRRs [189]. TLR3 and TLR7/8 has been shown to be important for the recognition of 
viral RNA [190-191]. TLR3 activation is associated with the induction of IFNβ and other 
pro-inflammatory cytokines and chemokines. The role of TLR signaling in anti-viral 
effects and in adaptive immune response is evident in studies associated with TLR-
deficient mice [186]. Following IAV infection, plasmacytoid DCs (pDCs) are the major 
candidates involved in production of type I IFNs, recognizing viral RNA via TLR7 and 
PKR. In contrast, myeloid DCs recognize viral RNAs by RIG-1 [186, 188]. NOD-like 
receptors (NLRs) are another class of PRRs. Inflammasomes is an important 
component of this class of receptors, and NLRP3 deficient mice have deficient innate 
response to IAV infection [192]. Along these lines, IL-1β deficient mice have reduced 
inflammatory response, with increased mortality and morbidity and deficient CD4+ T cell 
activation and decreased IgM response [193-194]. Retinoic acid-induced gene I (RIG-I)-
like receptors (RLRs) is another class of PRRs that includes RIG-I and melanoma 




strand 5’-triphoshate RNA and Mda-5 is activated by double-stranded RNAs. The 
signaling via these receptors initiates expression of type I IFN and other pro-
inflammatory cytokines [186]. IAVs inhibit the expression of type I IFNs via NS1 in 
several ways [195].  
IAVs infected alveolar macrophages produce pro-inflammatory cytokines 
including IL-6, TNF-α, IL-1β and IL-18 [185, 187, 196-197]. Infected lung epithelial cells 
secrete monocyte chemoattractant protein 1 (MCP-1) that attracts monocytes to the 
lung, differentiating into DCs and macrophages. Numerous studies have added 
information regarding the quality of cytokines and chemokines induced following 
influenza infection [185, 187]. The innate cytokine and chemokine response is important 
for recruitment of dendritic cells to the draining lymph nodes. Following influenza virus 
infection, the lung-resident dendritic cells up regulate the expression of MHC class II, 
costimulatory molecules, such as CD80, CD86 and CD40. These dendritic cells migrate 
to the draining lymph node, under the influence of the chemokine receptor, CCR7 and 
initate the adaptive immune response in the lymphoid tissue [198-199].  
T cell response  
Following influenza virus infection, CD8+ T cell response is regulated by several 
factors including FasL expression on DCs, TCR avidity, costimulation and inflammatory 
features in the lung [188, 200]. Within 6-7 days post infection, virus-specific T cells 
traffic to the lung, in response to several chemokines and chemokine receptor 
expression in the lung [201]. Virus-specific CD4+ and CD8+ T cells in the lung secrete 
IFN-γ and TNF-α and induce apoptosis of infected epithelial cells through FAS-FASL 
interactions or by secretion of perforin and granzymes. In contrast, CD4+ T cells also 
secrete IL-2 and IL-10 [188, 202-203]. CD8+ T cells play a critical role in virus 
clearance, as demonstrated by studies associated with mice lacking CD8+ T cells [204].  





The typical pattern of mucosal B cell response in the RT following influenza 
infection is depicted in Figure 1.5. Briefly, following influenza virus infection, virus-
specific IgM ASCs are generated in the draining lymph nodes, CLN and MLN. The early 
IgM response is dwarfed within a day or two by a peak of ASCs producing 
predominantly IgG isotypes. The response in the CLN, which is recognized as an IgA-
inductive site, typically includes a substantial proportion of IgA ASCs. IgA production is 
a less consistent feature of the MLN response, although a prominent early peak of IgA 
ASCs is seen in the MLN following infection with some influenza subtypes. An Ab 
response develops in the oNALT with the same kinetics as those in the CLN and MLN, 
but interestingly consists almost exclusively of IgA ASCs. Ab is produced locally by IgA 
and IgG antibody secreting cells (ASCs) that home to the RT. The majority of ASCs that 
localize in the upper RT secrete IgA [72], which is transcytosed across epithelial cells to 
establish a virus-neutralizing barrier at the mucosal surface. In addition to locally 
produced Ab, circulating IgG can enter respiratory tissues (particularly in the lower RT) 
by transudation, and this would be increased by virus-induced inflammation. Circulating 
IgG levels steadily increase from approximately day 7 after infection, initially reflecting 
Ab production in responding lymphoid tissues and later in the bone marrow (BM). The 
numbers of antiviral ASCs in all responding lymphoid tissues rapidly diminish after the 
elimination of infectious virus. However, antiviral Abs at the respiratory mucosa 
(particularly IgA) and in the blood are maintained long-term by the durable ASC 
populations that are established in the RT and the BM, respectively [46]. 
Virus-specific Abs plays an important role in the clearance of influenza virus 
[205]. In addition, virus-specific IgM early on in the B cell response is critical for virus 
clearance, reducing mortality and also protection from influenza-induced lung 
pathologies [206]. There is also an important role in virus clearance for other isotype-
switched Abs [207]. The cognate interaction between CD4+ T cells and B cells are 
important for B cell proliferation and isotype-switching [208]. Virus-specific IgA is CD4+ 
T cell dependent during the early stages of infection [209]. In addition, virus-specific IgG 




[210]. B cell memory is characterized by long-lived plasma cells and BMem. The 
generation of long-lived IgG ASCs is dependent on CD40 signaling as indicated [211] 
and these ASCs localize in the BM. Over long-term post infection, virus-specific IgG and 
IgA ASCs localize in the lung.  In contrast, IgA ASCs localize in the dNALT. Virus-
specific BMem circulate continuously and disperse to secondary lymphoid tissues, with 
spleen as a major repository of IgG BMem. In addition, both IgA and IgG BMem 















































Figure 1.1 Comparable acute phase pathogenesis following influenza virus or MHV-68 













TABLE 1.1 MHV-68 specific gene functions, adapted from [213] 
Gene                      Biochemical function Pathogenesis deficit 
M1 Secreted super-antigen like, induces 
expansion and activation, and 




M2 Modulation of BCR signal transduction 
[215], induces host IL-10, promotes 
plasma cell differentiation [139] 
Failure to reactivate [139], 
increased long term 
latency [216]    




M4 Not determined Latency establishment 
deficit [219] 
ORF8 gB, receptor binding Essential in vitro 
ORF11 Tegument protein Lytic replication deficit 
K3 Degrades MHC class I and TAP Latency amplification 
deficit 
ORF21 Thymidine kinase Severe lytic replication 
deficit 
ORF22 Virion fusion protein Essential in vitro 
ORF27 Cell-cell spread Lytic replication deficit 
ORF50/RTA Lytic cycle transcriptional activator Over-expression removes 
latency  
ORF51 gP 150 Release deficit in vitro, 
normal replication in vivo 
M11 Bcl-2 homolog, anti-apoptotic Reduced latency 
amplification and 
pathogenecity  













Figure 1.2. MHV-68 pathogenesis [213], highlighting the important proteins involved in 
various stages of the virus pathogenesis. Mucosal surfaces are the key sites of entry, 












                        
 
 


























           
                                                   
 























Figure 1.5. Typical pattern associated with mucosal B cell response to a virus 









Regulation of B cell response to a murine gammaherpesvirus-68 




A broad range of viruses representing multiple families enter the body via the 
respiratory tract (RT) and undergo a phase of replication in the respiratory mucosa. 
Although innate mechanisms provide early-acting antiviral activity, optimal control of 
primary viral infection of the RT is typically dependent on the development of Ag-
specific B and T cell responses. Highly effective B cell- and T cell-mediated antiviral 
mechanisms operate at sites of viral replication and the kinetics of development of these 
responses suggest that all play a role in viral clearance and recovery from infection 
[188]. 
 Studies over many years have generated a comprehensive picture of the 
development of B cell responses against viruses that target the RT and the role of Abs 
in viral clearance and long-term protection against re-infection. Much of this work was 
done using mouse models of acute infection with negative strand RNA viruses such as 
influenza A virus and murine parainfluenza type 1 (Sendai) virus [220-221]. Infection 
with these viruses is highly localized and transient; productive replication is restricted to 
epithelial cells from the nasal mucosa to the lower airways and recovery is associated 
with the complete elimination of virus from the body. B cell responses are first evident in 
secondary lymphoid tissues that drain the respiratory mucosa; most notably in the 
organized nasal-associated lymphoid tissue (oNALT), considered the murine equivalent 
of human tonsils [222], and in the cervical (CLN) and mediastinal (MLN) lymph nodes, 
which drain the upper and lower RT, respectively. The rapidity of the B cell response 
relates to Ag load, but virus-specific Ab production typically begins with the appearance 




IgM response is dwarfed within a day or two by a peak of ASCs producing 
predominantly IgG isotypes. The response in the CLN, which is recognized as an IgA-
inductive site, typically includes a substantial proportion of IgA ASCs. IgA production is 
a less consistent feature of the MLN response, although a prominent early peak of IgA 
ASCs is seen in the MLN following infection with some influenza subtypes. An Ab 
response develops in the oNALT with the same kinetics as those in the CLN and MLN, 
but interestingly consists almost exclusively of IgA ASCs. Ab production in the spleen 
matches the pattern in the CLN and MLN but is delayed by 2-3 days, presumably 
reflecting the time required for Ag transit from the lung [46]. From as early as 7 days 
after RT infection, Abs resulting from de novo B cell activation in secondary lymphoid 
tissues access sites of viral replication in the RT and contribute to viral clearance.  
Ab is produced locally by IgA and IgG antibody secreting cells (ASCs) that home 
to the RT. The majority of ASCs that localize in the upper RT secrete IgA [72], which is 
transcytosed across epithelial cells to establish a virus-neutralizing barrier at the 
mucosal surface. In addition to locally produced Ab, circulating IgG can enter respiratory 
tissues (particularly in the lower RT) by transudation, and this would be increased by 
virus-induced inflammation. Circulating IgG levels steadily increase from approximately 
day 7 after infection, initially reflecting Ab production in responding lymphoid tissues and 
later in the bone marrow (BM). Infectious virus is typically cleared from the RT between 
7 and 10 days after infection, correlating with the appearance of antiviral Ab in this 
location. The numbers of antiviral ASCs in all responding lymphoid tissues rapidly 
diminish after the elimination of infectious virus. However, antiviral Abs at the respiratory 
mucosa (particularly IgA) and in the blood are maintained long-term by the durable ASC 
populations that are established in the RT and the BM, respectively [46]. 
Murine gammaherpesvirus 68 (MHV68), belonging to the gammaherpesvirus 
sub-family, also targets the RT when administered intranasally (i.n.) to laboratory mice. 
Productive viral replication occurs in epithelial cells and mononuclear cells in the upper 
and lower RT [116]. Concurrently; a lifelong latent infection of B lymphocytes [59], 
macrophages [49], dendritic cells [123], and pulmonary epithelial cells [124] is 




distal sites, notably glandular tissues such as the salivary and mammary glands, where 
transient, low level replication may occur. Control of the acute phase of MHV68 
infection, with clearance of infectious virus from the RT by 10-12 days [156, 174], is 
mediated primarily by cytotoxic CD8+ T cells [156], and also effector CD4+ T cells that 
function via secretion of IFN-g [170]. These cells, together with antiviral Abs, continue to 
regulate the long-term persistent phase and the occasional re-emergence of infectious 
virus in the lungs and elsewhere [160, 179]. Features of the host response to MHV68 
infection include a massive splenomegaly peaking after approximately 2 wk [174] and 
reflecting expansion of the B cell (primarily) and T cell populations, and an infectious 
mononucleosis-like condition characterized by an increased frequency of activated 
CD8+ T cells in the peripheral blood [122, 168]. MHV68 infection in the mouse has many 
parallels with human Epstein Barr virus (EBV) infection and is considered a convenient 
experimental system that may provide valuable insights into g-herpesvirus infections in 
general [87, 89]. 
 Analyses of the B cell response to MHV68 infection that have been performed 
indicate a pattern that in many ways matches that described above for other viruses that 
replicate in the RT. Vigorous MHV68-specific B cell responses developed first in the 
CLN and MLN and somewhat later in the spleen. These responses, characterized by 
early IgM production followed by increased numbers of ASCs producing IgG isotypes, 
gradually waned after peaking between 2 and 3 wk after infection. A long-lasting ASC 
population was established in the BM and maintained high levels of circulating virus-
specific IgG. However, in marked contrast with the situation for other respiratory viruses, 
MHV68-specific IgA ASCs were absent from the responding lymph nodes, most notably 
the CLN [183]. In response to this observation, the current study was undertaken to 
comprehensively evaluate the B cell response to MHV68 infection, with an emphasis on 
the induction of virus-specific IgA and the establishment of Ab-mediated antiviral 
protection in the RT. Our analysis identifies a generalized deficiency in the MHV68-
specific IgA response that is a consequence of a strong bias towards Th1 cytokine 
production. In addition, our studies also demonstrate deficient mucosal B cell memory 




adaptation of viruses that establish long-term latency and are transmitted periodically 
after reactivation and shedding in secretions. Our findings also have implications for the 
control of g-herpesvirus infections by vaccination. 
 
Materials and Methods: 
Viruses 
MHV-68 (clone G2.4) was grown in owl monkey kidney cells and the stock titer 
was determined by plaque assay on NIH3T3 cells. Purified MHV-68 used for the 
immunoassays was prepared by sucrose density gradient centrifugation (collected at 
the interface of 30% and 60% sucrose gradients). The spontaneous deletion mutant, 
γHV68Δ9473 and the relevant WT γHV68 was obtained from Dr. Samuel Speck, Emory 
Vaccine center, Atlanta. Inactivated MHV-68 was prepared by UV-irradiating purified 
MHV-68, with a dose of 5000 rad. The UV-irradiation was carried out in Stratalinker, 
UV- crosslinker (model 2400).  An H1N1 Influenza A virus, A/New Caledonia/99 virus 
(NC), used for comparative studies was grown in the allantoic cavity of embryonated 
hen’s eggs. Purified NC (obtained from Dr.Richard Webby, St.Jude Children’s hospital, 
Memphis) was used for immunoassays. Inactivated NC was prepared by treating 
purified virus with β-propiolactone. The protein estimation in the purified virus was 
estimated by the Bradford assay [223].  
Mice  
C57BL/6J (B6) mice and mice deficient in IFN-γ signaling, B6.129S7-Ifngr1tm1Agt/J 
(IFNγ R-/-) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice 
were housed under pathogen-free conditions and after virus infection, were housed in 
BSL2-level containment. Females were used in all experiments and were infected at the 
age of 8-12 wk of age. The Animal Care and Use Committee of the University of 




Infection and sampling 
Mice were anesthetized i.p. with Avertin (2,2,2-tribromoethanol), followed by i.n. 
infection with viruses in 30µl of Dulbecco’s PBS. MHV-68 was administered as a dose 
of 10,000 PFU [183], unless indicated. NC was administered at a comparable dose of 
40,000 EID50. The anaesthetized mice were exsanguinated via the retroorbital plexus 
before tissue sampling. The superficial cervical lymph nodes (CLN) and the right 
posterior mediastinal lymph node (MLN) were collected and gently disrupted between 
frosted ends of microscope slides to generate single-cell-suspensions. The cells were 
re-suspended in IMDM (Invitrogen) containing L-glutamine (2 mM), sodium pyruvate (1 
mM), penicillin (100 IU/ml), streptomycin (100 µg/ml), gentamycin (10 µg/ml), 5x10-5 M 
β-mercaptoethanol and 10% FCS (Complete medium). Bone marrow (BM) cell 
suspensions were obtained by flushing femurs and tibiae. This was followed by RBC 
removal by using RBC lysis buffer (Sigma). Cell populations from o-NALT and d-NALT 
were collected as described previously [70]. Briefly, using the microscope, o-NALT was 
collected attached to the palate and cells were prepared by teasing. Cells in the d-NALT 
were recovered by digesting tissue lining the nasal passages with collagenase type I, 
followed by isolation by Percoll gradient centrifugation, as described for lungs. o-NALT 
and d-NALT were pooled from a set of three to four mice in order to obtain enough cells 
for the assay. Lungs were perfused with cold Dulbecco’s PBS, followed by fine mincing 
and incubation for 1hr at 37°C in complete medium that contained 4 mg/ml collagenase 
type II (Invitrogen). The cells from the lung were resuspended in 40% isotonic Percoll 
and gently layered over 75% isotonic Percoll (GE healthcare). The cells layered over 
the gradient was centrifuged at 2000 rpm for 20 min at 25°C and the cells at the 
interface of 40% and 75% isotonic Percoll was collected and washed with complete 
medium. Sera were collected from clotted blood. Nasal washes (NW) and lung washes 
(LW) were collected as described previously [224]. Briefly, NW was carried out by 
flushing 0.5ml of wash solution (0.1% BSA, antibiotics-PBS) into the trachea towards 
the nose, collected as it drained from the nares. LW was collected by injecting 1 ml of 




was repeated 4-5 times before final recovery. NW and LW were clarified by brief 
centrifugation and stored at -80°C, until further analysis. Lungs and nasal mucosa (NM) 
to be titrated for plaque assay were homogenized in 1 ml HBSS (Invitrogen) containing 
antibiotics and 0.1% BSA. The homogenates were clarified by centrifugation and the 
supernatants were stored at -80°C, until further analysis.      
ELISPOT assay 
The virus- specific ASCs were determined by ELISPOT assay as described 
previously [183]. Briefly, purified virus was detergent disrupted, and plated at 1 
µg/100µl/well in a 96- well multiscreen HA filter plates (Millipore). Following overnight 
incubation at 4°C, the plates were washed with PBS and blocked with complete medium 
for 1hr, 37°C, 5% CO2. 5X serial dilutions of cell suspensions were prepared in complete 
medium, and 100µl of the cells were added to the washed plates, beginning with 105 
cells/well, unless indicated. The plates were incubated for 4 hrs, 37°C, 5% CO2. This 
was followed by washes with Dulbecco’s PBS and 0.1% Tween-PBS. Alkaline 
phosphatase (ALP) conjugated isotype-specific goat anti-mouse Abs (Southern biotech) 
were diluted 1/500 in 5% BSA-PBS and added as 100µl/well, followed by overnight 
incubation at 4°C. After washing both sides of the plate, spots were developed at room 
temperature with 1 mg/ml of 5-bromo-4-chloro-3-indolyl phosphate (Sigma) in 
diethanolamine buffer. Thereafter, the plates were washed and dried. Each spot 
represents an antibody-secreting cell, and were enumerated visually by using an 
Olympus SZX9 microscope.   
ELISA assay 
The virus-specific Abs was determined by ELISA assay as described previously 
[183]. Briefly, purified virus was detergent disrupted, and plated at 0.25 µg/ 50 µl/well in 
a 96-well Nunc ImmunoMaxiSorp plates (Fisher-scientific). Following overnight 
incubation at 4°C, the plates were washed with 0.05% Tween-PBS and blocked with 3% 




or lung wash (LW) samples were prepared in 0.1% BSA-0.05%Tween-PBS, and 50 µl 
of the dilutions were added to the washed plates. The plates were incubated for 4hrs at 
room temperature and followed by washes. Alkaline phosphatase (ALP) conjugated 
isotype-specific goat anti-mouse Abs (Southern biotech) were diluted 1/600 to 1/1000 in 
1% BSA-PBS and added as 100µl/well, followed by overnight incubation at 4°C. After 
washing the wells, the plates were developed with p-nitrophenyl phosphate (Sigma) in 
diethanolamine buffer. After 20 min, absorbance at 405nm was read using a Vmax 
kinetic microplate reader (Molecular devices). The virus- specific Ab titer is expressed 
as the reciprocal of the highest dilution that gave an absorbance value more than twice 
that for the samples from naive mice. For some experiments, concentrations of Abs 
were calculated from standard curves based on purified mouse Ig standards (Southern 
biotech).  
Memory B cell assay 
Virus- specific memory B cells (BMem) were determined by memory B cell assay 
as previously described [46]. Briefly, in a 96-well round bottom plate, two-fold dilutions 
of cell-suspensions, beginning with 105 cells/well and were incubated for 3 days with 106 
X-ray irradiated (3000 rad) syngeneic naive splenocyte feeders and 0.1µg of inactivated 
virus. For MHV-68-specific memory B cell assays, UV-inactivated virus was used and 
for NC-specific memory B cell assays, β-propiolactone-inactivated virus was utilized. 
Following incubation, the cells were washed and transferred to detergent-disrupted virus 
coated plates, and ELISPOT assay (as described above) was carried out. Pre-existing 
virus-specific ASCs were also enumerated at the time of sampling by a direct ex vivo 
ELISPOT assay. Following ELISPOT analysis, the wells were scored positive for virus-
specific BMem if progeny ASC numbers were greater than twice the mean pre-existing 
ASC. The virus-specific BMem frequencies were calculated from the number of negative 
wells per cell dilution by extrapolation to the dilution that gave 37% negative wells [225]. 
BMem frequencies of less than one per 105 input cells could not be accurately 
determined. Virus-specific IgG and IgA BMem were defined as cells that generated IgG 





The virus titration on the homogenates derived from lung and NM were 
determined by plaque assay as described previously [133]. Briefly, 10-fold serial 
dilutions of the homogenates were prepared in DMEM (Biowhittaker) media 
supplemented with antibiotics and 10% FBS. 0.5 ml of the serial dilutions was added to 
6-well plates that had been previously seeded with a 70% confluent monolayer of 
NIH3T3 fibroblast cells. Dr. Tim Sparer, University of Tennessee provided the NIH3T3 
cells. The infected cells were incubated for 1hr at 37°C, 5% CO2. Following incubation, 
the virus dilutions were removed from cells. The infected cells were overlayed with a 
freshly prepared 3ml/well of 1.5% carboxy methyl cellulose (CMC) (Sigma) and 2X 
MEM media (Invitrogen) in a 1:1 v/v composition. The 2X MEM media was 
supplemented with 2x the amount of everything that was added to DMEM media, 
resulting in a 1X concentration in the overlay. This was followed by incubating the plates 
for 5-6 days at 37°C, 5% CO2. After 5-6 days, the overlay was removed and 1 ml of 1/50 
of glutaraldehyde (Acros) was added to each well for 10 min at room temperature to fix 
cells to plate. The glutaraldehyde was removed and 1ml/well of Coomassie blue stain 
was added. The staining was carried out for 45 min at room temperature, followed by 
washing and air-drying. The plaques were counted under microscope and PFU/ml was 
determined. Each plaque represents one plaque-forming unit.           
Statistics 
The statistical comparisons of mean values were performed using non-
parametric Mann-Whitney test (*p <0.05, **p <0.01).  
Results 
 
Deficient MHV-68-specific IgA and IgG1 induction in the RT 
              
Initial experiments evaluated the virus-specific B cell response in B6 mice 




enumerate virus-specific ASCs, including those generated during the acute response in 
secondary lymphoid tissues that drained the RT and also those that localized in the RT 
and BM that maintained long-term Ab production. NW and BAL were analyzed by 
ELISA to identify antiviral Abs available at the mucosal surfaces of the upper and lower 
RT. For comparison with the MHV68-specific response, a limited analysis of the virus-
specific response to i.n. infection with influenza A virus, NC was determined. The B cell 
response to NC represented the typical mucosal B cell response following RT infection. 
As described previously for the CLN and MLN, MHV68 infection generated a vigorous 
virus-specific ASC response, with early IgM production followed by a consistent 
predominance of IgG2b and IgG2c ASCs; IgA ASCs were essentially absent from both 
lymph nodes (Figure 2.1 A, D). Notably, few if any IgA ASCs were generated at any 
time in the oNALT (Figure 2.1 G), a site where IgA production typically predominates in 
the response to viruses that replicate in the RT [72]. Intranasal administration of a 
higher dose of MHV-68 did not change the profile of the B cell response (Figure 2.1 C, 
F). As expected, IgA was prominent in the NC-specific ASC response in the oNALT, in 
particular (Figure 2.1 H) and in the CLN (Figure 2.1 B). In addition, NC infection resulted 
in generation of high frequencies of IgG1 ASCs in the CLN and MLN (Figure 2.1 B, E). 
In contrast, IgG1 generation was largely absent from the MHV68-specific response 
(Figure 2.1 A, D), suggesting a stronger bias towards the induction of Th1 cytokines 
following MHV-68 infection. Similar trends were observed in the proportion of isotype-
switched virus-specific ASCs generated following MHV-68 or NC infection of the RT 
(Figure 2.2)     
             Virus-specific ASC populations were established in the BM after both MHV68 
(Figure 2.3 A) and NC (Figure 2.3 B) infection. Small numbers of MHV68-specific IgA 
ASCs were present in the BM on day 56, perhaps reflecting IgA ASC generation in the 
spleen later in the course of infection [183]. Virus-specific serum Ab levels closely 
reflected the differences in the ASC responses to MHV68 and NC infection. The IgG2b 
and IgG2c isotypes clearly predominated in serum after MHV68 infection (Figure 2.3 C), 
whereas IgG1, IgG2b, and IgG2c were at similar levels after NC infection (Figure 2.3 D). 




MHV68 infection. MHV-68-specific IgA was detected in the serum on day 56, reflecting 
IgA ASCs localization in the BM at this time-point.  
In contrast to the situation following NC infection, where IgA ASC localization in 
the RT correlated with IgA in the nasal washes, abbreviated as NW (Figure 2.4 F) and 
lung washes, abbreviated as LW (FIG. 4. J), virus-specific IgA was not detected in the 
NW (Figure 2.4 E) or LW (Figure 2.4 I) following MHV68 infection. MHV68-specific IgG 
was present in the LW from day 7 after infection (Figure 2.4 G) and also following NC 
infection (Figure 2.4 H). This probably reflects transudation of circulating Ab.  
 
Deficient MHV-68-specific B cell localization in the RT 
 
             During the acute phase of infection, the localization of ASCs in the d-NALT 
(NM) and lung was dramatically decreased after MHV68 (Figure 2.4 A, C) compared 
with NC infection (Figure 2.4 B, D). Interestingly, this applied not only to IgA ASCs, but 
also to IgG ASCs, suggesting a generalized difference in the regulation of ASC 
localization in the RT following MHV68 and NC infection. The analysis was extended to 
the memory phase of infection 56-84 days post infection. The deficiencies in MHV-68-
specific ASC localization in the NM (Figure 2.5 A) and lung (Figure 2.5 B), compared to 
NC infection were also reflected during the memory phase of infection. MHV-68-specific 
IgA was not detectable in the NW (Figure 2.5 C), compared to NC infection (Figure 2.5 
D). The MHV-68-specific IgG titers in the LW (Figure 2.5 E) were similar to the situation 
following NC infection (Figure 2.5 F). Compared to acute phase of infection, MHV-68-
specific IgA titers during the memory phase were detectable in the LW (Figure 2.5 G), 
although lower titers as compared to NC (Figure 2.5 H), probably reflecting the 
transudation of IgA from serum (Figure 2.5 C).         
Following influenza virus infection, virus–specific memory B cell (BMem) pool is 
established, which provide resistance to re-infection. The virus-specific BMem disperse to 
various secondary lymphoid organs such as the spleen and the MLN and are found in 




NC infection, the virus-specific IgG BMem response was analyzed using an ELISPOT 
based limiting dilution analysis [46, 226]. The frequencies of MHV-68-specific IgG BMem 
and NC-specific IgG BMem were comparable in the MLN and in the spleen. Surprisingly, 
both MHV-68 and NC- specific IgG BMem were found in low frequencies in the lung 
(Figure 2.6), perhaps reflecting virus modulated differences in the regulation of 
localization of immunologic memory in the RT. The generation of secondary MHV-68-
specific B cell response was determined by intranasal infection of mice that received 
splenocytes derived from either MHV-68 immune mice or naive mice. A strong 
secondary MHV-68-specific IgG response was evident in the group of mice that 
received immune cells, compared to the group of mice that received naive cells.  In 
addition, similar to the primary response, MHV-68-specific IgA was completely absent in 
the secondary response (Figure 2.7). Measurement of MHV68 titers demonstrated a 
transient phase of productive infection in both the upper and lower RT, with clearance of 
infectious virus by day 9 (Figure 2.8).  
 
Differential modulation of influenza-specific IgG and IgA response in the RT 
following MHV-68 and influenza virus co-infection 
  
            As NC infection of the RT induced a strong IgA and IgG1 production, a group of 
mice were co-infected with MHV-68 and NC and were compared with groups of mice 
that had been infected with either MHV-68 or NC. The purpose of co-infection studies 
was to determine if the MHV-68 induced environment in the RT influence NC-specific 
mucosal B cell response. The mice were first infected with MHV-68, and four hours 
later, infected with NC. The MHV-68- specific B cell response in the co-infected mice 
was identical to the mice that received MHV-68 alone. In contrast, the NC-specific B cell 
response in the co-infected mice was modulated by MHV-68 infection. In the co-infected 
mice, the NC-specific B cell response in the MLN exhibited down-regulated IgG1 
response, compared to NC single infected mice (Figure 2.9 & 2.10). In contrast, the NC-




was identical to the NC-specific response in the mice that received NC alone. Lack of 
effect of MHV-68 on the generation of X-31-specific IgA response was also observed 
following MHV-68 and X-31 co-infection (Figure 2.12, 2.13 & [46]). In contrast to the IgA 
response, but similar to the pattern observed with MHV-68 and NC co-infection, the 
down-regulation of IgG1, with an up-regulation towards IgG2c response was apparent in 
the draining lymph nodes of MHV-68 and X-31 co-infected mice, compared to X-31 
alone-infected mice (Figure 2.12 & 2.13). MHV-68-specific B cell response in the X-31 
co-infected mice remained unaltered, a feature consistent with NC co-infection studies.     
 
Increased influx of MHV-68-specific IgG influx into the lung following MHV-68 and 
influenza virus co-infection 
 
Following MHV-68 infection of the RT, there is a weak influx of virus-specific 
ASCs into the RT. As NC infection of the RT induced a strong influx of ASCs into the 
upper and lower RT, co-infection of MHV-68 and NC was carried out in order to test the 
influence of MHV-68 induced environment on NC -specific ASC influx into the RT. The 
localization of NC or MHV-68-specific ASCs into the BM, NM or lung was not affected 
by co-infection (Figure 2.11). Although not statistically significant, there was a trend 
towards increased MHV-68-specific ASCs in the lungs of co-infected mice. In contrast, 
following MHV-68 and X-31 co-infection studies, the influx of MHV-68-specific ASCs 
into the lung were significantly increased (Figure 2.14 A), compared to single infection, 
not affecting X-31-specific ASC localization into the lung (Figure 2.14 A). The influx of 
X-31 (Figure 2.14 B) [46] or MHV-68-specific  (Figure 2.14 C) ASCs into the NM were 
not affected as a result of co-infection.  
 





To determine whether MHV68 replication was a requirement for deficient virus-specific 
IgA induction, a concentrated preparation of MHV68 was inactivated by UV treatment 
prior to i.n. administration. It was necessary to administer a dose of inactivated particles 
equivalent to 30 µg of viral protein in order to generate consistently measurable B cell 
responses in the draining lymph nodes. Responses to inactivated MHV68 were 
relatively weak compared with responses to live virus infection, and they also differed 
substantially in Ab isotype profile. Inactivated MHV68 elicited predominantly IgA 
production in the CLN (Figure 2.15 A, B). The response in the MLN included a small IgA 
component, as well as IgG1 ASCs that were absent in the response to live virus (Figure 
2.15 C, D).  
 
Secondary B cell response to inactivated MHV-68 in the RT  
 
Similar to the live virus infection, a single dose of the inactivated MHV-68 did not 
induce localization of ASCs in the NM and lung. However, the group of mice that had 
been primed with inactivated MHV-68 and thereafter challenged with the inactivated 
MHV-68 three weeks later, demonstrated a massive influx of virus-specific IgG and IgA 
ASCs into the NM (Figure 2.16 F) and into the lung (Figure 2.16 E). In addition, the 
challenge also resulted in a strong secondary response to inactivated virus in the CLN 
(Figure 2.16 C) and in the MLN (Figure 2.16 D), which included both IgA and IgG1 
components. Priming mice with inactivated MHV-68 i.n. followed by live virus infection 
also resulted in a secondary B cell response in the CLN (Figure 2.16 A) and in the MLN 
(Figure 2.16 B) that included both IgA and IgG1 components. This reflects the ability of 
the live virus to activate a secondary B cell response induced by inactivated virus 
irrespective of the Ab isotype. The secondary B cell response to inactivated MHV-68 
following challenge with live virus was weaker compared to the secondary B cell 




MHV-68 acute phase replication associated gene products are not involved in 
down-regulating IgA response, but enhances influx of IgG ASCs into the lung  
       
The virus-specific IgA induction following inactivated MHV-68 administration 
indicates an influence of live virus replication on modulating the IgA response.  These 
findings suggest the possibility that MHV-68 associated gene products expressed 
during acute virus replication down-regulate the IgA response. To address this 
possibility, B cell response following intranasal infection of a spontaneous deletion 
mutant, γHV68Δ9473 was determined. The mutant virus lacks approximately 9.5 Kb of 
the unique coding sequence of MHV-68 genome [227]. This locus has at least twelve 
MHV-68 specific genes including M1, M2, M3, M4 and eight viral t-RNA-like genes [89] 
that are expressed both during acute virus replication and during persistence [108, 112, 
228-231]. Although the importance of this locus following an intranasal infection of 
γHV68Δ9473 was not completely characterized, an analysis following intranasal 
infection of MHV-76, another gammaherpesvirus isolate that has the locus deletion 
identical to γHV68Δ9473, revealed this locus to be important for acute virus replication 
in the lung and also for decreasing the host inflammatory response in the lung [121]. 
These findings suggest the possibility that MHV-68 may utilize this locus to down-
regulate host IgA response. In addition, M3 encodes for a chemokine binding protein, 
which is expressed in copious amounts in the lung [109, 155]. M3 can bind to several 
chemokines with high affinity [217], and therefore could potentially down-regulate the 
influx of virus-specific ASCs into the NM and lung.   
           The B cell response in the draining lymph nodes to the γHV68Δ9473 (Figure 2.17 
A, C) did not induce either IgG1 or IgA, and in these aspects were identical to the 
response to the corresponding WT γHV-68 (Figure 2.17 B, D). Interestingly, the IgG2c 
response was enhanced in the mice infected with γHV68Δ9473 compared to the mice 
infected with WT γHV-68. In addition, no virus-specific IgA was induced in the oNALT 




following γHV68Δ9473 infection, compared to the WT γHV-68 infection, with no changes 
in the influx of ASCs into the NM (Figure 2.17 G).   
 
MHV-68 specific IgA is induced following infection in the IFN-γR-/- mice 
 
As the MHV-68-specific gene products were not involved in the direct regulation 
of IgA and IgG1 induction, other features of MHV-68 replication in the RT, including a 
biased Th1 cytokine response [147] can potentially regulate the mucosal B cell 
response. Th1 responses can directly down regulate Th2 responses [232]. In addition, 
MHV-68 infection in the IFN-γR-/- mice results in induction of fibrosis, characterized by 
increased levels of TGFβ1 [233], a critical IgA class-switch factor [58, 61, 234-236]. 
Therefore, the change in the cytokine profile in these mice following MHV-68 infection 
could influence the B cell response. MHV-68 infection in the IFN-γR-/- mice generated 
IgA response in the CLN (Figure 2.18 A) and in the MLN (Figure 2.18 B) compared to 
the response in the WT mice. In contrast, IgA response was not generated in the 
oNALT of the IFN-γR-/- mice (Figure 2.18 F). IgG1 was also induced in the IFN-γR-/- 
mice following MHV-68 infection, indicating a role for IFN-γ in down-regulating Th2 
cytokine mediated class-switching mechanisms. Interestingly, the IgG2b proportions 
were increased, with a decrease in IgG2c proportions in the IFN-γR-/- mice following 
MHV-68 infection (Figure 2.19). 
 
Virus- specific ASC localization in the RT is impaired following infection in the 
IFN-γR-/- mice   
 
IFNγ induction in the RT following virus infection is an important signal for 
initiating chemokine cascade in the lung that can attract the immune cells to the RT. 
The MHV-68-specific localization of ASCs into the lung (Figure 2.18 C) and NM (Figure 




WT mice. Although the MHV-68-specific IgA ASCs were generated in the draining 
lymph nodes of IFN-γR-/- mice, these ASCs failed to localize the RT. Interestingly, NC-
specific IgA and IgG ASCs also failed to localize in the lungs of IFN-γR-/- mice, 
compared to WT mice (Figure 2.18 E). This indicates that the lack of localization of 
MHV-68-specific IgA and IgG ASCs in the lung following MHV-68 infection of the IFN-
γR-/- mice might be reflective of an inherent defect for ASCs to migrate to the lung in 




The B cell response to acute respiratory viruses that replicate in the RT, such as 
influenza virus and parainfluenza type 1 virus includes a substantial component of IgA 
[220-221]. MHV-68, a persistent gammaherpesvirus, following RT infection in mice 
offers as a good animal model for studying EBV immunobiology in vivo. Analysis of B 
cell response to MHV-68 revealed a marked contrast with the situation for other 
respiratory viruses. MHV68-specific IgA ASCs were absent from the responding lymph 
nodes [183]. Our analysis extends these studies, providing a comprehensive picture of 
the state of mucosal B cell response to MHV-68 infection of the RT. The analysis is 
compared with a typical mucosal B cell response generated following i.n. infection with 
a comparable dose of influenza A virus, NC. In addition, the current analysis also 
provides mechanistic insights into the regulation of B cell response to MHV-68 in the 
RT.  
One of the peculiar features, as demonstrated before, was an absence of IgA 
induction in the CLN following MHV-68 infection. This is surprising as CLN is a biased 
site for IgA induction following infection of RT [237-238]. Studies with other respiratory 
viruses have demonstrated that unlike oNALT in the upper RT, the draining lymph 
nodes have a larger proportion of IgG responses compared to IgA proportions. 
Increasing the load of MHV-68 in the RT increased the IgG proportions, but failed to 




antigen in the environment down-regulating MHV-68-specific IgA response. oNALT in 
the upper RT predominantly generates IgA ASCs following NC or other influenza 
viruses induction [46, 72]. In contrast, MHV-68 infection failed to generate IgA response 
in the oNALT. The lack of IgA generation was not associated with poor replication of 
MHV-68 in the RT, as MHV-68 replicated efficiently both in the nasal mucosa Figure 
2.8, [111, 114] and in the lung Figure 2.8, [115-116]. In fact, MHV-68 titers in the lung 
were comparable to the NC titers in the lung (data not shown). Failure to detect MHV-
68-specific secretory IgA in the NW and LW raises the scenario that along with the 
absence of IgA ASC generation, the secretion of IgA is also impaired, reflecting different 
levels of down-regulation of IgA by MHV-68 in the RT. Compared to the acute phase B 
cell response, some IgA ASCs were detectable in the BM during the memory phase of 
infection. Along these lines, IgA Abs were detected in the serum and in the LW, perhaps 
reflecting IgA ASCs generated in the spleen  [183] as a result of ongoing virus 
persistence and basal reactivation of virus.  
In contrast, the quantity of IgG responses was comparable between MHV-68 and 
NC infection, indicating an isotype-specific, selective down-regulation of virus-specific 
IgA following MHV-68 infection. The absence of IgA at mucosal surfaces in the upper 
RT extended into the memory phase of infection and this demonstrates a generalized 
deficiency of IgA induction following MHV-68 infection. All isotypes of the virus-specific 
Ab can be protective in nature, but lack of IgA offers defective Ab mediated protection, 
particularly at mucosal surfaces. The presence of influenza-specific IgA in the nasal 
passages has particularly anti-viral effects [134]. The absence of IgA at mucosal 
surfaces confers a selective advantage to MHV-68, as features of pathogenesis of virus, 
such as replication, latency establishment, reactivation and transmission are associated 
with mucosal surfaces of the RT [213]. EBV is detected in the secretions at tonsillar 
surfaces [134], which are equivalent to oNALT in mice [222]. Our studies demonstrating 
lack of IgA generation in the oNALT and also lack of secretory IgA Abs in the nasal 
wash following MHV-68 infection, perhaps reinforces the situation with EBV infection, 
facilitating virus replication and latency establishment in the RT, also favoring 




transmission models available, it would be potentially of interest to pursue the 
development of such models that demonstrate the role of IgA mediated mucosal 
protection to gammaherpesvirus infection.    
Our studies indicate that IgA and IgG induction mechanisms are differentially 
regulated in the RT. Following MHV-68 infection; the B cell response includes a bias 
towards IgG2b/IgG2c and no IgG1 induction. In contrast, NC infection of the RT has 
both IgGb/IgG2c and IgG1 components. This is perhaps reflective of the cytokine profile 
studies that demonstrate lack of typical Th2-associated cytokines such as IL-4, IL-5 
following MHV-68 infection [147], compared to other respiratory viruses, for example 
following sendai virus infection [239]. The effects of down regulation of Th2 associated 
cytokines by MHV-68 is also evident in the co-infection studies with MHV-68 and NC, 
which resulted in the down-regulation of NC-specific IgG1, favoring a strong bias 
towards IgG2c switching in the co-infected mice. In contrast, MHV-68-specific IgG 
isotype profile in the co-infected mice was identical to MHV-68 single infected mice. 
These results indicate a role for MHV-68 replication induced non-specific factors that 
perhaps favor the establishment of a biased Th1 environment in the RT involving a 
strong component of IFN-γ.  The features associated with this environment may be 
critical determinants regulating IgG isotype class switching mechanisms. Although we 
did not evaluate the cytokine profile of CD4+ T cells associated with co-infected and 
single-infected mice, the change in NC-specific IgG isotype pattern in the co-infected 
mice compared to NC single infected mice is indicative of a role for a biased component 
of IFN-γ derived form CD4+ T cells in modulating the IgG isotype class switching. IFN-γ 
production from CD4+ T cells during the process of cognate interaction with B cells is 
critical for the generation of virus-specific IgG2c [53]. In contrast, IL-4 production from 
Th2 cells is important for IgG1 isotype class switching [51-52]. It is also likely that the 
polarized Th1 environment following MHV-68 infection may play a direct role in down-
regulating Th2 differentiation [232]. This line of thinking is also observed in our studies 
with inactivated MHV-68 administration i.n. which resulted in the induction of IgG1 
response in the MLN. Indeed, inactivated MHV-68 is a relatively poor IFN-γ inducer, 




fibrosis associated with enhanced induction of Th2 cytokines including IL-4 [233]. In lieu 
of the altered cytokine pattern, we observed generation of IgG1 ASCs in the MLN of 
IFN-γR-/- mice infected with MHV-68. These findings favor the argument that a 
polarized Th1 environment can significantly down regulate Th2- mediated IgG1 class 
switching mechanisms. Interestingly, following a 9.5 Kb spontaneous deletion mutant 
(γHV68Δ9473) infection [227], the IgG2c response in the MLN was enhanced, reflecting 
a role for this region in regulating B cell response to MHV-68 in ways that is not yet 
clear. Additional step-wise characterization through individual loss-of-function mutants 
will be important to delineate the exact role of this region in regulating the B cell 
response to MHV-68.  
Although IgA class switching can occur via T cell-dependent and T-cell 
independent mechanisms [58], studies with influenza virus have demonstrated that the 
early generation of virus-specific IgA is entirely dependent on CD4+ T cell help [209]. 
CD40-CD40L interactions and TGF-β1 are known to regulate the classical T cell- 
dependent IgA class switching mechanisms [50, 58, 240]. CD40-CD40L interaction 
initiates NF-κB activation in B cells, leading to induction of activation induced cytidine 
deaminase (AID) [60]. AID is critical for class switch recombination process and IgA 
class switching [241]. Low concentrations of TGF-β1 is important for initiating Cα 
transcription, resulting in the generation of germline Cα transcripts that makes the 
transcripts amenable to the actions of AID, inducing IgA CSR [61]. Although the source 
of TGF-β1 in the context of T cell-dependent scenario is not clear, certain subsets of 
CD4+ T cells can directly secrete TGF-β1 [242] and perhaps induce IgA class switching. 
Alternatively, Th2-derived cytokines, such as IL-4, IL-5 and IL-10 may also stimulate B 
cells to secrete endogenous TGF-β1 that can induce IgA class switching in an autocrine 
fashion [243]. The other possibility is that TGF-β1 secreted by CD4+ T cells or in an 
endogenous manner by B cells may be important for the generation of IgA plasmablasts 
which following exposure to Th2-derived cytokines may differentiate and proliferate into 
IgA plasma cells [10]. In contrast, our studies demonstrate no roles for Th2 mediated 




affected in the co-infected mice, although NC- specific IgG1 induction was impaired in 
these mice. Unlike IgG isotypes, the IgA class-switching mechanism is not inhibited by 
the polarized IFN-γ environment, contrary to a study that demonstrated direct inhibition 
of TGFβ1-mediated IgA class switching by IFN-γ signaling on B cells [244].  Although 
we did not compare the proportions of TGF-β1 secreting CD4+ T cells following NC or 
MHV-68 infection, unlike NC, MHV-68 establishes latency in all the antigen presenting 
cells [49, 57, 59] and therefore can potentially down regulate the differentiation of 
subsets of TGF-β1 secreting CD4+ T cells that aid in IgA class switching.   
Our studies indicate that the deficient IgA induction following MHV-68 infection is 
a feature associated with virus replication, as inactivated MHV-68 induced a 
predominating IgA response in the CLN, with some IgA response being generated in the 
MLN as well. The induction of predominantly IgA ASCs in the CLN, compared to MLN 
following inactivated virus administration is also evident in studies with influenza [226]. 
This may be indicative of features associated with inactivated virus, which are perhaps 
sampled by M cells in the epithelial cells of NALT to the DCs resulting in the selective 
generation of IgA committed plasmablasts [10]. These cells may then migrate to the 
CLN through the efferent lymphatics and therefore, following inactivated virus 
administration, there is mainly appearance of IgA ASCs in the CLN. In contrast, live 
virus replication may be associated with induction of other mechanisms that favor 
generation of ASCs in the CLN, rather than migration of ASCs from NALT, resulting in 
the localized generation of IgG ASCs and IgA ASCs in the CLN.  Induction of IgA to 
inactivated MHV-68 implicated features of live virus replication in down regulating IgA 
response. But, MHV-68 associated gene products expressed during the acute phase of 
infection did not influence IgA induction as demonstrated by our studies with the 9.5Kb 
spontaneous deletion mutant, γHV68Δ9473. It would be interesting perhaps to examine 
TGFβ1 induction following administration of inactivated MHV-68.  
Availability of increased TGF-β1 in the environment can contribute to IgA 
induction to live virus, as observed with our studies following MHV-68 infection in the 




with increased TGFβ1 induction [233]. Interestingly, MHV-68 infection in the IFN-γR-/- 
mice failed to induce IgA response in the oNALT, pointing towards a differential 
regulation of IgA induction in the upper and lower RT. Alternatively; it is also likely that 
the pattern of fibrosis may be associated in the lower RT and not with the upper RT, 
contributing to differential induction of TGF-β1 in the upper and lower RT following 
infection of MHV-68 in the IFN-γR-/- mice.  The B cell response in the draining lymph 
nodes of these mice also included increased IgG2b proportions. This may reflect the 
ability of TGFβ1 to induce both IgA and IgG2b class switching. Interestingly, IL-21 
causes an effective down-regulation of TGFβ1-mediated class switch to IgG2b, without 
influencing TGFβ1 mediated effects on class-switch to IgA. Therefore, the strikingly 
strong IgG2b component in these mice may also reflect decreased IL-21 in the TGF-
beta rich microenvironment [245]. Further characterization of cytokine profiles in the 
upper and lower RT of these mice will be required to address these issues.   
The B cell response to respiratory viruses replicating in the RT includes 
generation of cellular elements of B cell memory, consisting of virus-specific ASCs 
producing IgG and IgA, as well as concentrations of BMem that localize in the RT [46]. In 
contrast to NC and other influenza virus infection, MHV-68 infection resulted in a weak 
influx of IgG ASCs into the RT at all times post-infection. This is surprising, as both NC 
and MHV-68 generated comparable IgG responses in the draining lymph nodes. 
Mechanisms regulating trafficking of ASCs into the lung and NM are not clear. IgG 
ASCs expressing CXCR4 traffic to BM in response to the corresponding ligand, 
CXCL12 [31]. This feature does not seem to be compromised following MHV-68 
infection, as there is comparable IgG ASCs localization in the BM following NC or MHV-
68 infection. In addition, IgG ASCs expressing CXCR3 traffic to inflammatory sites 
[246]. Following MHV-68 or influenza infection, there is an apparent inflammation in the 
lung, with both viruses inducing BALT structures [247-248]. But, the inflammation 
induced in the lung following MHV-68 infection may be compromised as indicated by 
studies following MHV-76 infection of the RT. MHV-76 is a gammaherpesvirus isolate 
that has genes missing similar to the spontaneous deletion mutant, γHV68Δ9473. 




inflammatory response in the lung [121], raising questions that perhaps, the lung 
inflammation induced by MHV-68 is sub-optimum. In support of this line of thinking, our 
analysis of B cell response to γHV68Δ9473 revealed increases in the frequencies of 
ASCs in the lung. Significant increases were not observed in the NM, compared to the 
frequencies following WT virus infection. The ASCs localizing in the NM are mostly IgA 
ASCs, and as γHV68Δ9473 infection similar to the WT virus failed to generate IgA 
ASCs, the influx of ASCs into the NM remained comparable. The increased influx of 
ASCs into the lung may also reflect the lack of effects of the chemokine binding protein, 
M3 in the mutant virus. M3 is secreted in large amounts in the lung during the acute 
phase of infection [217], and may contribute to the modulation of inflammation in the 
lung. Although, a previous study demonstrated no changes in the chemokine pattern in 
the lung following infection with a virus lacking M3 coding sequence [152], there could 
be localized effects of M3 that can modulate the immune response. It is not known if M3 
is secreted in the NM. Therefore, the weak influx of IgG ASCs into the lung, perhaps are 
modulated by the threshold of inflammation in the RT, dictated by the nature of infecting 
virus. These lines of thoughts were also apparent following infection with different 
strains of influenza, as NC (a non-mouse adapted virus) infection of the RT resulted in 
lower frequencies of IgG and IgA ASCs localizing in the lung and NM, compared to the 
X-31 or PR8 infection (mouse adapted viruses) [46]. Inflammation in the lung as a 
possible stimulus for attracting IgG ASCs into the lung was also evident following 
inactivated MHV-68 or inactivated influenza administration, which attracted little IgG 
ASCs to the lung [226]. Co-infection with X-31 encouraged significant influx of MHV-68-
specific ASCs into the lung, and this kind of a trend was also observed following NC and 
MHV-68 co-infection, although not statistically significant. This could reflect the 
increased inflammation or other factors in the lung by X-31, compared to NC infection. 
Alternatively, the nature of infecting virus may modulate the induction of ASCs that are 
inherently programmed to enter the RT.  
The IgA ASCs generated in the lymph nodes draining the RT are pre-
programmed to migrate to the lung [249]. Therefore, it is surprising that although IgA 




migrate to the lung. The failure of IgA and IgG ASCs to migrate to the lung seems to be 
an inherent defect in these mice as NC infection of IFN-γR-/- mice also resulted in 
reduced appearance of IgA and IgG ASCs in the lung. These studies also emphasize a 
role for IFNγ in modulating the influx of ASCs into the RT. Following inactivated X-31 
administration i.n., there is a preferential localization of IgA ASCs in the lung and NM 
[226]. In contrast, in the lung, although the magnitude of MHV-68-specific IgA ASCs 
was comparable to the X-31-specific IgA ASCs, the administration of inactivated MHV-
68 resulted in localization of both IgG and IgA ASCs in the lung. These differences may 
be due to the generation of higher frequencies of IgG ASCs in the MLN following 
inactivated MHV-68 administration, compared to those induced following inactivated X-
31 administration [226].  
IgG BMem frequencies in the MLN and spleen following MHV-68 and NC infection 
were similar, but both the viruses-specific IgG BMem’s failed to localize in the lung. In 
contrast, following X-31 infection, greater frequencies of IgG BMem localized in the lung 
[46]. It is not clear what mechanisms govern the trafficking properties of BMem into the 
lung. This may reflect properties of IgG BMem, similar to ASCs , being modulated by the 
nature of infecting virus and threshold of inflammation in the lung. Induction of BALT 
does not seem to be a requisite for attracting or maintaining ASCs or BMem in the lung, 
as BALT is induced following influenza or MHV-68 infection. Perhaps, the properties of 
BALT induced following MHV-68 infection may be different from that following influenza 
infection, as BALT seems to be a latent reservoir for MHV-68 [248]. In contrast to the 
situation following influenza infection, IgA BMem is not generated following MHV-68 
infection, as indicated by the adoptive transfer studies. 
Priming mice with inactivated MHV-68 i.n. generated elements of both IgG and 
IgA BMem, as indicated by the strong secondary B cell response in the draining lymph 
nodes following challenge with inactivated MHV-68 or live MHV-68. The B cell response 
induced by the challenge possessed typical secondary B cell response features, 
characterized by a reduction in IgM response and an increase in the isotype-switched B 
cell responses compared to the primary response. These studies indicate that the 




of virus replication. The generation of a secondary B cell response with IgG1 and IgA 
components indicates that the live MHV-68 has the ability to differentiate BMem to ASCs 
irrespective of the Ab isotype. Interestingly, priming mice with inactivated MHV-68 
generated both IgG, IgA BMem that following differentiation with inactivated MHV-68 
localized in the lung and NM. Our studies indicate that inactivated MHV-68, in contrast 
to live virus can induce IgA, and also enhance localization of both IgG and IgA ASCs in 
the upper and lower RT.   
In summary, the current studies provide a comprehensive picture of B cell 
response to MHV-68 in the upper and lower RT and also address possible mechanisms 
contributing to MHV-68 mediated down regulation of virus- specific IgA and IgG1. In 
addition, these studies provide a platform for testing inactivated MHV-68 as a potential 
vaccine strategy in providing mucosal protection to gammaherpesvirus infection. The 
findings lead to the speculation that deficient B cell-mediated mucosal protection 
modulated by virus replication may represent an evolutionary adaptation of viruses that 
establish long-term latency and are transmitted periodically after reactivation and 

























































Figure 2.1. Virus-specific B cell response in the upper and lower respiratory tract. B6 
mice were infected i.n. with 10,000PFU of MHV-68 or 40,000 EID50 of NC. The kinetics 
of MHV-68- specific ASC response in the CLN (A), MLN (D) and o-NALT (G) is shown. 
For comparison, limited analysis of NC-specific ASC response was determined in the 
CLN (B), MLN (F) and o-NALT (H). Virus-specific ASC response in the CLN (C) and 
MLN (F) was determined on day 10 post-infection with a higher dose of MHV-68 (2x105 
PFU). The ELISPOT assay was performed on cell suspensions of CLN and MLN 
derived from individual mice, and for o-NALT, the cell suspensions were pooled from 
three to four mice. The ASCs producing virus-specific IgM, IgG1, IgG2b, IgG2c, IgG3 
and IgA were determined. Results are expressed as a frequency of ASCs per 105 
nucleated cells. The mean + SE for the draining lymph nodes is shown for five to twelve 
individual mice and the mean + SE for o-NALT is shown for three to six sets of pooled 
































Figure 2.2. Proportion of isotype switched virus- specific ASCs in the upper and lower 
respiratory tract. Following 10 days post infection, the proportions were determined in 
the CLN and MLN following MHV-68 infection (A & C respectively) and following NC 
infection (B & D respectively). Proportions of MHV-68 and NC-specific IgA ASCs among 
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Figure 2.3. Circulating virus-specific B cell response. The kinetics of MHV-68-specific 
ASC response in BM (A) was determined following MHV-68 infection and compared 
with a limited NC-specific ASC analysis in BM (B). ELISPOT assay was performed on 
cell suspensions derived from individual mice and numbers of cells producing virus-
specific IgM, IgG, and IgA were determined. Results are expressed as a frequency of 
ASCs per 5x105 nucleated cells. The mean + SE is shown for five to thirteen individual 
mice. The kinetic analysis of virus-specific IgM, IgG1, IgG2b, IgG2c, IgG3 and IgA 
serum Ab levels were determined following intranasal infection with MHV-68 (C) and NC 
(D). ELISA assay was performed to determine virus- specific titers by end-point titration. 














Figure 2.4. Virus-specific B cells localization in the RT during the acute phase of 
infection. The kinetics of MHV-68 -specific ASCs in the NM (A) and lung (C) was 
determined by ELISPOT assay. The analysis was compared with the NC-specific ASCs 
in the NM (B) and lung (D) on day 21 post infection. The mean + SE for lung is shown 
for three to ten individual mice. The mean + SE for NM is shown for three to five sets of 
pooled samples from individual infected mice. The samples were analyzed as described 
in legend to figure 1. Following infection with MHV-68 or NC infection, ELISA assay was 
performed to determine the levels of MHV-68-specific Ab levels in the NW (E) and LW 
(G,I) and NC-specific Ab levels in the NW (F) and LW (H,J). The mean + SE is shown 
for five to thirteen individual mice. The samples were analyzed as described in legend to 



































Figure 2.5. Virus-specific B cells localization in the respiratory tract during the memory 
phase. 56-84 days after infection, the virus -specific ASCs in the NM (A) and lung (B) 
was determined by ELISPOT assay following intranasal infection with MHV-68 or NC. 
Results are expressed as a frequency of ASCs determined per animal. ELISA assay 
was performed to determine the levels of MHV-68-specific Ablevels in the NW (C) and 
LW (E, G) and NC-specific Ab levels in the NW (D) and LW (F, H) following infection 
with MHV-68 or NC respectively. The mean + SE is shown for three to six individual 



































Figure 2.6. Quantitative analysis of virus-specific IgG Bmem in the MLN, spleen and lung. 
B6 mice were sampled 8-12 wk after i.n. infection with MHV-68 or NC. IgG BMem 
frequencies are expressed as proportions per organ, determined by LDA based on in 
vitro stimulation of BMem by inactivated virus to differentiate into ASCs. The stimulation 
was carried out by incubating BMem with 0.1µg of inactivated virus. The scatter of the 






























Figure 2.7. MHV-68-specific secondary B cell response. Splenocytes from MHV-68 
immune B6 mice or naïve B6 mice were adoptively transferred into irradiated (400 rad) 
naïve B6 mice. Each mouse, 3x107 cells were transferred via i.p and i.v routes. 
Following the transfer, the recipient mice were i.n. infected with 10,000 PFU of MHV-68. 
7 days after infection, the recipient mice were sampled and the frequency of MHV-68-
specific ASCs was determined by ELISPOT assay in the MLN (A). Results are 
expressed as a frequency of ASCs per 105 nucleated cells. The level of MHV-68-
specific Abs in the serum, nasal wash and lung wash on day 7 post-infection was 
determined by ELISA assay (B). The concentrations of Abs were determined by 
standard curves generated by using purified mouse immunoglobulin standards. The 























Figure 2.8. MHV-68 replication in the upper and lower respiratory tract. B6 mice were 
infected with 10,000 PFU of MHV-68 i.n. and at indicated times after infection, lungs 
and NM were harvested and virus titers determined in the homogenates by plaque 
assay on NIH3T3 cells. The horizontal dotted line indicates the sensitivity of the assay, 

















Figure 2.9. Virus-specific B cell response following co-infection of MHV-68 and NC. B6 
mice were infected i.n. with 10,000 PFU OF MHV-68 and after four hours, infected with 
40,000 EID50 of NC. The ASC response in the CLN (A), MLN (B), o-NALT (C) is shown. 
The ELISPOT assay for CLN and MLN was performed on cell suspensions derived from 
individual mice and for o-NALT on pooled samples from three mice. Results are 
expressed as a frequency of ASCs per 105 nucleated cells. The mean + SE for the CLN 








Figure 2.10. Proportions of isotype-switched virus-specific B cells following MHV-68 and 
NC co-infection. NC-specific ASC response in the CLN (A), MLN (C) and in the oNALT 
(E) is shown. MHV-68-specific ASC response in the CLN (B), MLN (D) and in the 








Figure 2.11. Virus-specific B cell response following co-infection of NC and MHV-68. B6 
mice were infected i.n. with 40,000 EID50  of NC and after four hours, were infected with 
10,000PFU of MHV-68. The ASC response in the lung (A), d-NALT (B), BM (C) on 34-
35 days post infection is shown. The ELISPOT assay for lung and BM was performed 
on cell suspensions derived from individual mice and for d-NALT on sets of pooled 
samples from three mice. Results are expressed as a frequency of ASCs per 105 
nucleated cells for lung and d-NALT and as ASCs per 5x105 nucleated cells for BM. The 












Figure 2.12. Virus-specific B cell response following co-infection of MHV-68 and X-31. 
B6 mice were infected i.n. with MHV-68 and after two days, infected with X-31. X-31- 
specific ASC response in the co-infected mice are indicated as follows; CLN (A), MLN 
(B), oNALT (C), dNALT (I). X-31-specific ASC response in X-31 alone-infected mice are 
indicated as follows; CLN (G), MLN (H). MHV-68-specific ASC response in the co-
infected mice are indicated as follows; CLN (D), MLN (E), oNALT (F). The ELISPOT 
assay for CLN and MLN was performed on cell suspensions derived from individual 
mice and for o-NALT on pooled samples from three mice. The mean + SE for the CLN 










































Figure 2.13. Proportions of isotype-switched virus-specific B cells following MHV-68 and 
X-31 co-infection. X-31-specific IgG1 response is down regulated, while IgG2c response 
is enhanced following MHV-68 and X-31 co-infection. The X-31-specific ASC response 
in the CLN (A), MLN (B) and in the oNALT (C) is shown. Results are shown for three to 
eight individual mice. The co-infected mice were sampled on day 11-post MHV-68/ day 



























         
 
 
Figure 2.14. Virus-specific B cell response following co-infection of MHV-68 and X-31. 
Virus-specific ASC response in the lung (A) on day 30 post MHV-68 infection/day 28 
post X-31 infection, comparing co-infected and respective single infected mice is shown. 
X-31-specific ASC response in the dNALT (B) of co-infected mice on day 28 post 
infection is shown. MHV-68-specific ASC response in the dNALT (C), comparing co-
infected and MHV-68 alone on day 30 post-infection is shown. The ELISPOT assay for 
lung was performed on cell suspensions derived from individual mice and for dNALT on 
sets of pooled samples from three mice. The mean + SE for lung dNALT is shown for 
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Figure 2.15. MHV-68-specific B cell response to inactivated virus. C57BL/6 mice were 
i.n. administered with 30µg of UV-inactivated MHV-68. The MHV-68 -specific B cell 
response was determined by ELISPOT assay in the CLN (A) and in the MLN (C). 
Results in the CLN are expressed as a frequency of 5x105 of nucleated cells and in the 
MLN as a frequency of 105 nucleated cells. The proportions of isotype switched virus- 
specific ASCs in the CLN (B) and MLN (D) are shown. The mean + SE is shown for 








Figure 2.16. MHV-68-specific secondary B cell response following priming with 
inactivated MHV-68. 3 wks post i.n. immunization of B6 mice with 30µg of inactivated 
MHV-68, the mice were either challenged with 2x105 PFU of MHV-68 or boosted with 
30µg of inactivated MHV-68. MHV-68-specific B cell response in CLN (A), MLN (B) 
following challenge with the live virus is shown. Results are expressed as a frequency of 
105 cells. The mean + SE is shown for four individual mice. The MHV-68 -specific 
response in the CLN (C), MLN (D), lung (E) and d-NALT (F) following challenge with the 
inactivated virus was determined. As a result of a weaker B cell response, results in 
CLN are expressed as a frequency of 5x105 cells, and results in other sites are 
expressed as a frequency of 105 cells. The mean + SE for CLN, MLN and lung is shown 












Figure 2.17. Virus-specific B cell response to γHV68Δ9473. B6 mice were i.n. 
administered with 4x105 PFU of γHV68Δ9473 or WT γHV68. The frequencies of MHV-
68- specific ASCs following γHV68Δ9473 infection in the CLN (A) and MLN (C) is 
shown. For comparison, MHV-68-specific B cell response to WT γHV68 in the CLN (B) 
and in the MLN (D) was determined. In addition, comparison of frequencies of MHV-68-
specific ASCs following γHV68Δ9473 or WT γHV68 infection was determined in the o-
NALT on day 10 post-infection (E), lung (F) and in the d-NALT (G) on day 21 post 
infection. Results are expressed as ASCs per 105 nucleated cells, determined by 
ELISPOT assay. The mean + SE for MLN, CLN and lung samples are shown for four to 
eight individual mice. The mean + SE for o-NALT and d-NALT is shown for three sets of 





































Figure 2.18. MHV-68-specific B cell response in the IFN-γR-/- mice. B6.129S7-
Ifngr1tm1Agt/J (designated as IFNγR-/-) and the background strain, B6 mice (designated 
as WT) were i.n. administered with 104 PFU of MHV-68. The frequencies of MHV-68- 
specific ASCs were determined by ELISPOT assay on the cell-suspensions derived 
from CLN (A), MLN (B), dNALT(C) and lung (D). The frequencies of NC-specific ASCs 
in the lung (E) are shown. The lung and d-NALT analysis were carried out on day 21-
26-post infection. Results are expressed as ASCs per 105 nucleated cells. The mean + 
SE for MLN, CLN and lung samples are shown for three to six individual mice. The 
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Figure 2.19. Proportion of class-switched MHV-68-specific ASCs in the IFN-γR-/- mice. 
Responses in the CLN and MLN following infection in the WT mice (A & C respectively) 








Regulation of B cell response to influenza virus following infection of 




Studies of mouse models of influenza A virus infection have produced a 
comprehensive picture of disease pathogenesis and the innate and adaptive antiviral 
mechanisms that contribute to viral clearance and recovery [220-221]. The initial phase 
of influenza virus replication in epithelial cells of the upper and lower respiratory tract, as 
well as viral targeting of local macrophages and dendritic cells, triggers the rapid 
release of a range of cytokines and chemokines with antiviral and pro-inflammatory 
activity [188]. In addition to limiting viral replication in the respiratory tract, these 
processes are critical for the optimal activation of Ag-specific B and T cells and the 
development of adaptive immunity. The ultimate elimination of infectious virus from the 
respiratory tract is dependent on B and T cell-mediated mechanisms, such as the 
destruction of virus-infected cells by infiltrating cytotoxic CD8 T cells, and the antiviral 
activity of progressively increasing antibody levels [250-251]. 
Optimal virus-specific antibody production following influenza infection in the 
mouse is dependent on CD4 T cell help for B cells [252]. Although some antiviral 
antibodies can be generated in the absence of CD4 T cells, antibody production is 
substantially more vigorous and effective following collaborative interactions between 
CD4 T cells and B cells [210]. CD4 T cells provide cognate signals and secreted factors 
that drive B cell activation and differentiation and induce antibody isotype switching. 
After cognate interactions of peptide:MHC class II (MHC II)-bearing B cells with CD4 T 
cells, activated B cells may differentiate via the extrafollicular pathway to rapidly 




or they may enter B cell follicles and initiate germinal center reactions where long-
lasting populations of ASCs and memory B cells expressing high affinity antiviral 
antibody are formed [253] . The progression of B cells through the germinal center 
reaction is dependent on a second phase of a cognate T cell help delivered by follicular 
helper T cells [254]. Regulation of the differentiation options available to B cells 
responding to influenza infection is not well understood. In addition, little is known about 
the relationship between the repertoire and quality of the influenza-specific CD4 T cell 
response and the provision of cognate help for an optimally effective B cell response. 
Recently, the influenza-specific CD4 T cell response was comprehensively 
characterized in HLA-DR1 transgenic (DR1) mice, which express as a transgene a 
hybrid MHC II molecule consisting of the peptide-binding domain of human HLA-DR1 
and a membrane-proximal region of mouse origin [255]. Infection of DR1 mice with 
A/New Caledonia/20/99 (NC) (H1N1) resulted in a virus-specific CD4 T cell response 
that was predominantly restricted to the transgenic MHC II molecule. The response 
repertoire was exceptionally broad and included multiple strong epitopes in the four viral 
proteins analyzed: HA, NA, NP, and nonstructural protein 1 (NS1) [256]. Although 
initially used as a tool for the identification of MHC II-restricted epitopes that may be 
relevant to responses in humans, DR1 mice now provide a model that is well-
characterized at the level of CD4 T cell responses to a recently circulating influenza 
virus.  
In the current study, the virus-specific B cell response in DR1 mice following NC 
infection was analyzed as a step towards relating characteristics of the influenza-
specific CD4 T cell response to B cell response parameters and the effective production 
of antiviral antibodies. C57BL/10 (B10) mice, which share the non-MHC genetic 
background of DR1 mice and provide a contrasting CD4 T cell response pattern, were 
included for comparison. Whereas the NC-specific CD4 T cell repertoire in DR1 Tg 
mice, as described above, was particularly broad, B10 mice displayed a much narrower 
repertoire with fewer epitopes largely confined to the NA and NP. We demonstrate 
striking differences between DR1 and B10 mice in the virus-specific B cell response to 




strains were used for infection and by non-specific effects during concurrent infection 
with NC and an unrelated virus. Overall, our findings indicate that the nature/quality of 
the extrafollicular B cell response depends on the nature of the infecting virus. We 
present evidence that this pathway of rapid antiviral antibody production relates to the 
production of non-specifically acting factors in the lung and correlates with the cytokine 
profile of virus-specific CD4 T cells. 
 
Materials and Methods 
Viruses 
Influenza A viruses, A/New Caledonia/99 virus (NC) and A/Puerto Rico/8/1934 
virus (PR8) were grown in the allantoic cavity of embryonated hen’s eggs. Purified NC 
(obtained from Dr.Richard Webby, St.Jude Children’s hospital, Memphis) and purified 
PR8 was used for immunoassays. MHV-68, a gammaherpesvirus (clone G2.4) was 
grown in owl monkey kidney cells and the stock titer was determined by plaque assay 
on NIH3T3 cells. Purified MHV-68 used for the immunoassays was prepared by sucrose 
density gradient centrifugation (collected at the interface of 30% and 60% sucrose 
gradients).The protein estimation in the purified virus was estimated by the Bradford 
assay [223]. Purified HA (Protein Sciences Corp. Meriden, CT) and purified NP 
(provided by Dr. Andrea Sant, University of Rochester, Rochester) were used in some 




The HLA-DR1 transgenic mice (B10.M/J-TgN-DR1) [255] were obtained from D. 
Zaller (Merck) through Taconic laboratories and were maintained in the pathogen-free 
facility at the University of Tennessee according to institutional guidelines. These mice 
express a chimeric HLA-DR1 class II molecule, whose peptide binding domain is 




murine I-E. This design facilitates interaction with murine CD4 T cells. For comparison, 
B10 mice (C57BL/10) were purchased from the Jackson Laboratory (Bar Harbor, ME). 
Mice were housed under pathogen-free conditions and after virus infection, were 
housed in BSL2-level containment. Females were used in all experiments and were 
infected at the age of 8-12 wk of age. The Animal Care and Use Committee of the 
University of Tennessee approved animal procedures.  
 
Infection and sampling 
 
Mice were anesthetized i.p. with Avertin (2,2,2-tribromoethanol), followed by i.n. 
infection with viruses in 30µl of Dulbecco’s PBS. NC was administered at 40,000 EID50, 
PR8 at 25EID50, MHV-68 at 10,000 PFU [183], unless indicated. The anaesthetized 
mice were exsanguinated via the retroorbital plexus before tissue sampling. The right 
posterior mediastinal lymph node (MLN), spleen were collected and gently disrupted 
between frosted ends of microscope slides to generate single-cell-suspensions. The 
cells were re-suspended in IMDM (Invitrogen) containing L-glutamine (2 mM), sodium 
pyruvate (1 mM), penicillin (100 IU/ml), streptomycin (100 µg/ml), gentamycin (10 
µg/ml), 5x10-5 M β-mercaptoethanol and 10% FCS (Complete medium). Bone marrow 
(BM) cell suspensions were obtained by flushing femurs and tibiae. This was followed 
by RBC removal by using RBC lysis buffer (Sigma). Lungs were perfused with cold 
Dulbecco’s PBS, followed by fine mincing and incubation for 1hr at 37°C in complete 
medium that contained 4 mg/ml collagenase type II (Invitrogen). The cells from the lung 
were resuspended in 40% isotonic Percoll and gently layered over 75% isotonic Percoll 
(GE healthcare). The cells layered over the gradient was centrifuged at 2000 rpm for 20 
min at 25°C and the cells at the interface of 40% and 75% isotonic Percoll was collected 




ELISPOT assay for B cells 
The virus- specific ASCs were determined by ELISPOT assay as described 
previously [183]. Briefly, purified virus was detergent disrupted, and plated at 1 
µg/100µl/well in a 96- well multiscreen HA filter plates (Millipore). Following overnight 
incubation at 4°C, the plates were washed with PBS and blocked with complete medium 
for 1hr, 37°C, 5% CO2. 5X serial dilutions of cell suspensions were prepared in complete 
medium, and 100µl of the cells were added to the washed plates, beginning with 105 
cells/well, unless indicated. The plates were incubated for 4 hrs, 37°C, 5% CO2. This 
was followed by washes with Dulbecco’s PBS and 0.1% Tween-PBS. Alkaline 
phosphatase (ALP) conjugated isotype-specific goat anti-mouse Abs (Southern biotech) 
were diluted 1/500 in 5% BSA-PBS and added as 100µl/well, followed by overnight 
incubation at 4°C. After washing both sides of the plate, spots were developed at room 
temperature with 1 mg/ml of 5-bromo-4-chloro-3-indolyl phosphate (Sigma) in 
diethanolamine buffer. Thereafter, the plates were washed and dried. Each spot 
represents an antibody-secreting cell, and were enumerated visually by using an 
Olympus SZX9 microscope.   
ELISA assay 
The virus-specific Abs was determined by ELISA assay as described previously 
[183]. Briefly, purified virus was detergent disrupted, and plated at 0.25 µg/ 50 µl/well in 
a 96-well Nunc ImmunoMaxiSorp plates (Fisher-scientific). For HA and NP- specific Ab 
detection, the required concentrations of these proteins were dissolved in PBS and 
directly added to the plates. Following overnight incubation at 4°C, the plates were 
washed with 0.05% Tween-PBS and blocked with 3% BSA-PBS for 90 min at room 
temperature. Serial dilutions of serum or nasal wash (NW) or lung wash (LW) samples 
were prepared in 0.1% BSA-0.05%Tween-PBS, and 50 µl of the dilutions were added to 
the washed plates. The plates were incubated for 4hrs at room temperature and 
followed by washes. Alkaline phosphatase (ALP) conjugated isotype-specific goat anti-




as 100µl/well, followed by overnight incubation at 4°C. After washing the wells, the 
plates were developed with p-nitrophenyl phosphate (Sigma) in diethanolamine buffer. 
After 20 min, absorbance at 405nm was read using a Vmax kinetic microplate reader 
(Molecular devices). The virus- specific Ab titer is expressed as the reciprocal of the 
highest dilution that gave an absorbance value more than twice that for the samples 
from naive mice. For some experiments, concentrations of Abs were calculated from 
standard curves based on purified mouse Ig standards (Southern biotech).  
HA- specific Antibody affinity ELISA 
This is a modified ELISA assay, based on Sodium thiocyanate (NaSCN) 
displacement of low-affinity Abs. Through titration of sera in the presence of various 
concentrations of NaSCN (Sigma), a discriminating concentration of 0.75M NaSCN was 
identified (data not shown). Briefly, the dilutions of sera were incubated in the HA- 
coated wells. This was followed by addition of 0.75M NaSCN or PBS (as a control) to 
the wells, and 15 min incubation at RT was carried out. This was followed by washes, 
and incubation for 2 hrs at RT in the presence of ALP-conjugated IgG goat anti-mouse 
Ab (Southern biotech).  Thereafter the plates were developed as described above, and 
read using a Vmax kinetic microplate reader (Molecular devices). A standard curve 
based on purified mouse Ig standards (Southern biotech) was used for the calculation of 
concentrations of Abs in the sera. This was followed by calculation of Avidity index (AI).  
AI = Concentration of Abs with NaSCN/Concentration of Abs without NaSCN x 100. 
Flow cytometry 
The cells derived from MLN were stained with the appropriate combination of 
FITC-labeled PNA (Vector laboratories), Alexa-647-labeled anti-FAS (BD biosciences), 
PE (Cy7)-labeled anti-CD4 (RM4-5, BD biosciences), anti-CD8 (53-6.7, ebioscience), 
PE (Cy5.5)-labeled anti-CD19 (eBio 1 D3, ebioscience), PerCP-labeled anti-B220 (RA3-
6B2, BD biosciences), APC labeled anti-CD138 (281-2, BD biosciences) after blocking 
of the Fc receptor with naive serum at 4 ˚C. Data were acquired by using LSR II (BD 




gate was drawn to include lymphocyte populations from FSC Vs SSC. This was 
followed by removal of doublets and was gated on live cell populations using live/dead 
fixable aqua dead cell stain kit (Invitrogen). For identifying germinal center B cells, the 
cells were gated on B220+ populations, followed by gating on PNA+FAS+ cells. For 
identifying plasma cells, the cells were gated on B220lo/int CD138+ cells.     
 
Cytokine production by influenza-specific CD4+ T cells analysis 
 
Briefly, enriched CD4+ T cells from MLN were cultured in vitro with APCs and a 
range of class-II restricted peptide epitopes. Cytokine production was determined by 
ELISPOT assay after 24 hrs [256].  
 
Statistics 
The statistical comparisons of mean values were performed using non-




Altered NC-specific extrafollicular ASC response in DR1 mice 
 Initial experiments compared the virus-specific B cell response in DR1 and B10 
mice following intranasal infection with the H1N1 influenza virus NC. Infection in both 
mouse strains was sublethal and virus was completely cleared from the lung after 
transient replication. Virus titers in the lung on days 1, 3, 5, and 8 after infection were 
similar in DR1 and B10 mice, indicating comparable Ag loads [268] A strong virus-
specific IgM and IgG ASC response was evident in the draining mediastinal lymph node 
(MedLN) of DR1 and B10 mice on day 8, whereas IgG ASCs were essentially absent 




mice was typical of previously reported influenza-specific B cell responses in a range of 
mouse models and included a strong IgG2b and IgG2c component. In contrast, when a 
NC-specific IgG response developed in DR1 mice (see MedLN on day 14), it was 
strongly biased to IgG1 production [268] (Figure 3.1 A, B). NC-specific ASC localization 
in the bone marrow of DR1 and B10 mice reflected the kinetics and isotype profile of 
responses in lymphoid tissues [268]. Infection with a high (sublethal) dose of NC did not 
substantially modify the differences between DR1 and B10 mice in the characteristics of 
the NC-specific ASC response in the MedLN [268]. 
The B cell response in the MedLN after NC infection was also characterized by 
flow cytometry. On day 8, the percentage of B220+ B cells (mean ± SD) was similar in 
the MedLN of DR1 and B10 mice (50.52 ± 3.398 and 50.44 ± 5.072, respectively). 
Contrary to the pattern for NC-specific ASCs measured by ELISPOT assay, the 
proportion of B220int CD138+ phenotype of ASCs generated by the extrafollicular 
pathway was similar between DR1 and B10 mice (Figure 3.2 B, D). In contrast, the 
proportion of germinal center cells (PNA+ Fas+) in the B220+ cell population was 
approximately 3-fold higher in DR1 mice, suggesting stronger germinal center activity. 
The proportion of germinal center B cells increased from day 8 to day 10 in B10 mice, 
but remained significantly lower than in DR1 mice (Figure 3.6 B, D). Depletion of CD4 T 
cells essentially eliminated NC-specific ASCs in the MedLN of B10 mice on day 8, 
establishing that the early ASC response in B10 reflected T-dependent B cell 
differentiation and not T-independent antibody production (Figure 3.2 E). Overall, our 
findings indicate more rapid generation of NC-specific isotype-switched B cell response 
in B10 mice that was largely absent from DR1 mice. 
 
Discordance between ELISA measurements of NC-specific serum antibodies and 
virus neutralization titers 
Measurement of NC-specific serum antibody levels by ELISA demonstrated a 
significantly more rapid IgG response in B10 compared with DR1 mice; primarily 




not follow this pattern and were significantly higher in DR1 mice on days 14 and 21, 
perhaps reflecting the high frequency of IgM ASCs in the spleen on day 14 [268]. NC-
specific serum Ig levels, which provide a measure of all antibodies with virus 
neutralizing potential, were significantly higher in B10 compared with DR1 mice on day 
8 and similar at later sampling times [268]. Overall, ELISA measurements of NC-specific 
serum antibodies were consistent with the pattern of ASC generation in lymphoid 
tissues. 
In a surprising contrast to the pattern of NC-specific serum antibody levels in 
DR1 and B10 mice demonstrated by ELISA, the trend was for higher early virus 
neutralization titers in DR1 mice [268]. This difference was particularly striking on day 
14. HAI titers in DR1 and B10 mice closely paralleled the neutralization titers [268]. 
Since virus neutralization in vitro and inhibition of viral hemagglutination is mediated by 
antibodies specific for the viral HA molecule, an early antibody response in DR1 mice 
characterized by higher virus neutralization and HAI titers, but not higher ELISA titers of 
antiviral antibodies, raised the possibility of a stronger HA-specific antibody response 
and/or generation of higher affinity HA-specific antibodies. The production of virus-
specific antibodies with higher binding affinity in DR1 mice would be consistent with the 
stronger germinal center response. 
 
Anti-HA and anti-NP analysis 
 
Following NC infection in the DR1 mice, there is a stronger germinal center B 
response, with stronger virus neutralization and HAI titers, compared to NC infection in 
B10 mice. In addition, the CD4+ T cell repertoire following infection in the DR1 mice was 
exceptionally broad and included multiple strong epitopes in the four viral proteins 
analyzed: HA, NA, NP, and nonstructural protein 1 (NS1), in comparison to B10 mice 
which had restricted epitopes in HA [256]. Therefore, the levels of anti-HA and anti-NP 
Abs were measured in the sera derived from DR1 and B10 mice infected with NC. In 




affinity in DR1 and B10 mice. On day 10 post-NC infection, the pattern of anti-HA and 
anti-NP Abs in the serum paralleled the trend observed with virus-specific Abs 
differences observed between B10 and DR1 mice (Figure 3.4 A). In contrast, on day 14 
post-NC infection, the anti-NP Abs in B10 and DR1 still paralleled the trend observed on 
day 10, but the anti-HA Abs in the DR1 mice did not follow the day 10 trend, while the 
anti-HA Abs in the B10 mice followed the same trend as day 10 (Figure 3.4 B). The 
affinity ELISA on day 14 sera did not reveal any differences between B10 and DR1 mice 
(Figure 3.4 C).             
 
The virus-specific B cell response in DR1 mice is substantially modulated 
by the nature of the infecting virus 
  
Total serum levels of IgM and the IgG isotypes were not significantly different 
between DR1 and B10 mice (data not shown), suggesting that in general, the 
predominance of IgG1 in the response of DR1 mice to NC infection did not reflect an 
intrinsic bias impacting B cell responses. We therefore compared B cell responses in 
DR1 and B10 mice after infection with other influenza viruses (PR8 and X31), or with a 
non-influenza virus (MHV68) that replicates in the lung. Infection of DR1 mice with PR8, 
X31, or MHV68 generated a virus-specific B cell response in the MedLN that, in many 
respects, was more comparable to the response in B10 mice than was the case 
following NC infection (Figure 3.5). Most notably, the kinetics of the IgG response was 
similar in DR1 and B10 mice, and the IgG1 bias of the response of DR1 mice to NC 
infection was no longer present. Interestingly, there was a markedly stronger IgM ASC 
response in DR1 compared with B10 mice after PR8, X31, and MHV68 infection, a 
trend that was also evident, but much less pronounced, after NC infection.  
 The response to PR8 infection in DR1 and B10 mice was evaluated in greater 
detail.  Virus titers in the lungs (TCID50/ml ± SD) were similar in both mouse strains on 
day 6 (4.4 x 106 ± 3.9 x 106 for DR1 and 9.5 x 105 ± 7.9 x 105 for B10) and day 8 (1.3 x 




replication and Ag load. Flow cytometric analysis of cell populations in the MedLN on 
day 8 after PR8 infection showed similar percentages of B220+ B cells (mean ± SD) in 
DR1 and B10 mice (50.99 ± 3.599 and 46.79 ± 8.762, respectively). In marked contrast 
to the situation after NC infection, the proportion of B220int CD138+ was higher in DR1 
compared with B10 mice (Figure 3.2 C, D), reflecting the vigor of the early PR8-specific 
IgM response in DR1 mice measured by ELISPOT assay. The proportion of germinal 
center cells (PNA+ Fas+) in the B220+ cell population was significantly higher in DR1 
compared with B10 mice (Figure 3.6 C, E), as was also the case after NC infection, 
suggesting an inherent tendency towards a stronger germinal center response in DR1 
mice regardless of the infecting virus. The PR8-specific response in DR1 mice was 
evaluated after CD4 T cell depletion, since high frequencies of IgM and, to a lesser 
degree; IgG3 ASCs raised the possibility of T-independent antibody production. CD4 T 
cell depletion largely prevented PR8-specific ASC formation in the MedLN of DR1 mice 
on day 8 (Figure 3.2 F), indicating a dependence of the early and strong IgM and IgG3 
ASC response on T cell help. Our findings indicate that PR8 infection, but not NC 
infection, generated a vigorous early extrafollicular B cell response in DR1 mice. Unlike 
the situation in DR1 mice, the kinetics of ASC generation in B10 mice was not obviously 
increased after PR8 compared with NC infection (Figure 3.2 D), emphasizing the 
influence of host factors on the extent that different viruses modulate the B cell 
response. 
 Serum levels of virus-specific antibody were consistent with comparable B cell 
responses in DR1 and B10 mice after PR8 infection. Although there was a trend 
towards higher neutralization titers in DR1 compared with B10 mice on day 10 [128], 
reflecting the pattern seen after NC infection, the difference was not significant. Overall, 
our experiments using PR8, X31, and MHV68, in comparison to the results after NC 
infection, demonstrated that the kinetics and quality of the B cell response to respiratory 





Contrasting B cell responses to NC and PR8 in DR1 mice relates to CD4 T cell 
cytokine production 
 
 The extrafollicular and germinal center pathways of B cell differentiation are T 
cell-dependent processes [12]. In addition, cytokines produced by T cells during 
cognate interactions with B cells play a key role in directing the expression of particular 
Ig isotypes [257]. We therefore investigated the relationship between the B cell 
response in DR1 and B10 mice following infection with NC or PR8 and the 
characteristics of the virus-specific CD4 T cell response, in particular the pattern of 
cytokine production. To evaluate the CD4 T cell response, purified CD4 T cells from the 
MedLN and spleen on day 10 after infection were tested for their ability to produce 
cytokines after stimulation with peptides corresponding to previously defined epitopes. 
Peptide-reactive CD4 T cells stimulated to secrete IL-2, IFN-g, or IL-4 during in vitro 
culture were quantified by ELISPOT assay. 
 Following NC infection, in the MedLN on day 10, there was a difference between 
DR1 and B10 mice in the pattern of cytokine production by peptide-specific CD4 T cells. 
This pattern was largely independent of peptide specificity and generally reflected the 
mouse strain. Peptide-reactive CD4 T cells in the MedLN of DR1 mice consisted of 
similar numbers of IL-2, IFN-γ-secreting cells and IL-4-secreting cells (Figure 3.7). In 
contrast, in the MedLN of B10 mice, very few IL-4-secreting cells, some IL-2-secreting 
cells were observed and IFN-γ-secreting cells predominated (Figure 3.8). The results 
described above were essentially the same in an analysis of CD4 T cells in the MedLN 
on day 13 after NC infection (data not shown). The prevalence of virus-specific IL-4-
secreting CD4 T cells in DR1 but not B10 mice suggested a basis for the IgG1 bias of 
the NC-specific response, since IL-4 has been shown to promote switching to IgG1 and 
negatively regulate switching to other IgG isotypes [258-259]. 
 An analysis of the CD4 T cell response was also performed on day 10 after PR8 
infection of DR1 and B10 mice. As described above, the PR8-specific B cell response in 
DR1 and B10 mice featured similarly strong early extrafollicular B cell responses. In 




Supporting the B cell response, the pattern of cytokines secreted by peptide-reactive 
CD4 T cells after PR8 infection in DR1 largely differed from the pattern after NC 
infection (Figure 3.9, 3.10). Interestingly, this pattern of cytokine production was also 
different from B10 mice infected with PR8. Most notable was the higher proportion of IL-
4-secreting CD4 T cells in DR1 mice (Figure 3.9) compared to B10 mice (Figure 3.10). 
Apparently, the IgG1 bias of the NC-specific B cell response in DR1 mice was driven by 
the high prevalence of IL-4-secreting CD4 T cells. Our findings suggest that the nature 
of the extrafollicular B cell response is dependent of the pattern of cytokines secreted by 
virus-specific CD4 T cells. 
 
The virus-specific B cell response in DR1 mice is substantially modulated by non-
specific factors associated with infection 
 
 We hypothesized that the markedly different B cell responses in DR1 mice 
following infection with NC compared with PR8 (and other viruses tested) reflected 
differences in early innate responses to lung infection. This idea was tested in a co-
infection experiment using NC and MHV68. We had shown that the MHV68-specific B 
cell response in DR1 and B10 mice followed similar kinetics and featured IgG2c 
predominance among switched antibody isotypes. IgG or IgA ASCs were not detected 
when cells from mice infected with NC or MHV68 alone were incubated on ELISPOT 
plates coated with the heterologous virus, indicating an absence of cross-reactivity 
between NC and MHV68 at the B cell level (Data not shown). 
 Cohorts of DR1 and B10 mice were infected with NC plus MHV68, or with NC 
only, and the B cell response on days 8 and 10 was assessed by ELISPOT assay using 
plates coated with NC or MHV68 (Figure 3.11). The NC-specific response in DR1 mice 
infected with NC alone was dramatically modified by concurrent MHV68 infection and 
closely resembled the response in B10 mice infected with NC alone. Importantly, the 
NC-specific IgG response in co-infected DR1 mice was not delayed relative to the 




levels of NC-specific IgG and Ig on day 8 were also consistent with a more rapid NC-
specific response in co-infected DR1 mice compared with those infected with NC alone 
(Figure 3.11 E, F). Our findings establish that non-specific factors associated with 
infection of the lung by some viruses have the potential to substantially modulate the 
isotype switching and isotype bias of a virus-specific B cell response. Our interpretation 




Effective generation of B cell response to viruses is largely dependent on CD4+ T 
cell help and it is unclear how these interactions best achieve effective generation of 
neutralizing antibodies. Generation of effective B cell response is central for vaccine 
design and protection against re-infection. Following infection, the antigen engaged B 
cells receive cognate help from CD4+ T cells and undergo either of the following 
pathways of B cell differentiation. 1.  Migration to extra follicular foci in the spleen or in 
the medullary cords of draining lymph nodes, initiating the extra-follicular pathway of B 
cell differentiation [19], that generates low affinity and rapid Abs. 2. B cell proliferation in 
follicles leading to germinal center (GC) formation and generation of delayed, but high 
affinity Abs [12]. Although several mechanisms have been proposed that delineate the 
choice between these pathways of differentiation [13-15], it is still largely unclear, 
especially in the context of virus infection, host and viral factors regulating extra 
follicular or GC pathway of B cell differentiation. Our analysis identifies HLA-DR1 
transgenic mice as a model for the investigation of the addressed issues, providing 
insight into the host and viral factors that modulate the characteristics of B cell response 
to influenza infection.  
Following NC infection in DR1 mice, there is a delay in the generation of virus-
specific isotype-switching, compared to NC infection in B10 mice. Rapid isotype 
switching response in the B10 mice is characteristic of an extra-follicular B cell 




pathway in the DR1 mice. The nature of extra follicular pathway of B cell differentiation 
is regulated by the induction of non-specific factors in the lungs, as indicated by the co-
infection studies with MHV-68 and NC. Manipulation of these factors by MHV-68 and 
also the fact that PR8 infection generates a rapid B cell response in these mice 
emphasize the point that lack of isotype-switching towards extra follicular B cell 
differentiation following NC infection in DR1 mice is not an inherent feature of these 
mice, but rather seems to be regulated by viral factors. There may also be an interplay 
of host factors as well, indicated by our comparative preliminary innate cytokine and 
chemokine analysis in the lung (data not shown). These studies indicate that the DR1 
mice have a delayed or much lower generation of certain cytokines and chemokines 
which may be critical for the initiation of a down stream rapid isotype switching. An 
elaborate analysis of these innate factors following PR8 or MHV-68 infection in the DR1 
mice will identify virus induced host factors that may provide mechanistic insights into 
these processes. Although the early B cell response is of low affinity, our studies 
indicate that these extra- follicular generated B cells may perhaps contribute to virus 
clearance as indicated by delayed virus clearance pattern associated with DR1 mice.   
   Cytokines secreted by CD4+ T cells during cognate interaction with B cells are 
critical mediators that induce isotype switching of B cells [253, 257, 260]. Our studies 
indicate that this rule applies to extrafollicular B cells as well, contrary to a study that 
demonstrated extra follicular IgG1 class switching unimpaired in the absence of IL-4 
[261]. Our analysis indicates that there is a good correlation between the pattern of 
cytokines produced by CD4+ T cells and the corresponding isotype of Abs. The H1N1 
viruses; NC and PR8 tested in this study induced different pattern of CD4+ T cell 
cytokine in the DR1 mice, but a similar pattern in the B10 mice. Following infection in 
DR1 mice, NC seems to favor a strong IL-4 induction, while PR8 seems to favor more of 
IFN-γ, along with IL-4. Interestingly, the PR8-specific Ab isotype pattern is not entirely 
the same between B10 and DR1 mice, with a bias towards IgG3 and an early strong 
IgM isotype in the DR1 mice. The IgM and IgG3 Ab phenotype is associated with CD4+ 
T cell independent mechanisms, and our CD4+ T cell depletion studies indicate that 




some of the non-CD4+ T cell derived factors may be involved in the extra-follicular Ab 
generation, that are also involved in T cell independent Ab generation. The IgG3 bias 
may perhaps reflect the combinatorial effects of IL-4 and IFN-γ in the microenvironment. 
For example, TGF-β1 alone is capable of inducing both IgG2b and IgA class switching. 
In contrast, TGF-β1 in the presence of IL-21 inhibits TGF-β1 mediated class switching 
to IgG2b, without influencing IgA class switching [245]. There seems to be a role for 
non-specific factors in the isotype bias, as co-infection studies with MHV-68 and NC 
resulted in removal of the IgG1 bias in the DR1 mice.     
Although it is not clear what virus dictated mechanisms in these mice induce the 
Th1 versus Th2 differentiation, it is likely that perhaps the APCs presenting the peptides 
to the naïve T cells might be differentially modulated by these viruses. For example, 
dendritic cells (DCs) can be conditioned by NC to polarize naïve T cells to be 
differentiated towards Th2 cells, while PR8 favoring Th1 cells. Innate signals can drive 
conditioning of DCs as Th2 polarization is MyD88 signaling independent, while Th1 
polarization is MyD88 dependent [262]. In addition, in the absence of IL-12, Th2 
polarization is preferred [263]. Along these lines, it would be interesting to characterize 
the B cell response, perhaps following immunization of DR1 mice with rIL-12 and infect 
them with NC or alternatively following infection of IL-12-/- mice with NC. Other factors, 
including enhancement of Notch signaling, up regulation of CD40 [263] and OX40L 
[264]on APCs are also key determinants favoring Th2 over Th1 differentiation.           
   There is a stronger GC induction on day 8 following NC or PR8 infection in the 
DR1 mice, compared to B10 mice. Although, NC infection in the DR1 seem to imply that 
the extra follicular pathway of B cell differentiation is compromised at the expense of GC 
reaction, analysis of PR8 infection in the DR1 mice revealed that this might not be the 
case, as GC and EF were pathways were induced normally. Our studies have 
demonstrated that the strong GC induced in these mice is completely CD4+ T cell-
dependent process (data not shown), as some GC reactions can be generated 
independent of CD4+ T cells [265]. Therefore, this argues for a CD4+ T cell derived 
influence on a strong GC reaction. In this direction, one of the players could be the 




observed in these mice, irrespective of the infecting virus. Indeed, IL-4 has an important 
role in maintaining GC reactions [26]. Although our studies do not identify the CD4+ T 
cell subset producing IL-4, one possible candidate is follicular helper T cells (Tfh), which 
produce IL-4 and also regulate B cell responses in the GC reaction [266-267]. In fact, 
there is a good correlation between Tfh cells and GC numbers. Another scenario that 
could explain stronger GC in the DR1 is that these mice may be biased towards IL-21 
production, as lack of IL-21 or IL-21R on B cells results in reduced germinal centers, 
with reduced Bcl-6 expression in germinal center B cells [24-25]. Apart from the 
importance of IL-21 in germinal center reactions, there is also a role for IL-21 in 
regulating IgG1 class switching, as the germinal center B cells in mice lacking IL-21R 
fail to class-switch to IgG1. Other studies have also identified Th17 cells, through IL-21 
production, to be important players in inducing a strong GC [27]. In addition, the 
stronger GC in the DR1 may also be linked to the pattern of innate factors induced in 
the lung. Therefore, further studies characterizing these different CD4+ T cell subsets in 
the DR1 mice will be important to address these issues.  
NC infection in the DR1 mice also induced stronger neutralizing Abs and HAI 
titers, compared to B10 mice. Although there was a similar trend following PR8 
infection, the titers did not reach statistical significance in the DR1 mice, perhaps 
reflecting stronger GC proportions on day 10 following NC infection. In contrast, by this 
time post infection, the GC proportions in the DR1 mice following PR8 infection were 
similar to B10 mice. Indeed, neutralizing Abs is established in the serum at least 2 
weeks post infection. Another possible explanation explored in the current study is that 
there is perhaps a bias towards the generation of HA-specific Abs in the DR1 mice. This 
is based on the comparison of CD4+ T cell repertoire to NC infection, which revealed a 
broad recognition (multiple epitopes recognized in multiple viral proteins including HA). 
In contrast, the repertoire in B10 mice was narrow (recognition of few epitopes, mostly 
in NP) [256]. In support of this thinking, on day 14 post NC infection, there was a trend 
towards higher HA-specific Abs in the DR1 mice. Further studies, contrasting the 
findings following PR8 infection will be important. The broad repertoire of Abs do not 




which also have a broad repertoire, similar to DR1 mice did not induce an IgG1 bias 
(data not shown).  
In summary, these studies establish a model for the investigation of host and 
viral factors that modulate the quality and effectiveness of the B cell response to 
influenza infection. These studies indicate that the strength of the extrafollicular pathway 
of rapid antiviral production is modulated by host factors and by the nature of infecting 
virus. In addition, the regulation of the extrafollicular pathway relates to the induction of 
non-specifically acting factors in the lung by viral infection and also to the pattern of 
cytokines produced by virus-specific CD4+ T cells.   
 










































































Figure 3.1. The NC-specific ASC response in DR1 mice is biased towards IgG1 
production. DR1 and B10 mice were infected intranasally with 40,000 EID50 NC. Virus-
specific ASC frequencies in the MedLN were determined by ELISPOT assay on day 14. 
The IgG isotypes proportions are shown. The proportions were determined for 3-8 













Figure 3.2. Extrafollicular ASC generation in DR1 and B10 mice after NC or PR8 
infection. A-D, MedLN cells from DR1 and B10 mice on day 8 after intranasal NC or 
PR8 infection were analyzed by flow cytometry. Single cell suspensions from individual 
mice were stained and gated for expression of B220 and CD138 to identify 
extrafollicular ASCs, defined as a B220int CD138+ population. Representative staining 
for extrafollicular ASCs is shown for naive mice (A) and on day 8 after infection with NC 
(B), PR8 (C). Staining is shown as 5% contour plots, with the number indicating the cell 
frequency in the depicted gate. Mean frequencies of extrafollicular ASCs are compiled 
in D. Frequencies + SE is shown for 4-8 individual mice in each group. NC-specific ASC 
frequencies in CD4 T cell-depleted B10 mice and mock-depleted control mice on day 8 
after infection is shown (E). PR8-specific ASCs in CD4 T cell depleted DR1 mice and 
mock-depleted control mice on day 8 after infection is shown (F). The mean + SE is 








Figure 3.3. Serum levels of NC-specific antibody in DR1 and B10 mice. Different assays 
were used to determine NC-specific antibody levels in sera collected at intervals after 
infection. A-H, Antibody titers measured by ELISA. NC-specific IgM (A), IgG1 (B), IgG2b 
(C), IgG2c (D), IgG3 (E), IgA (F), IgG (G), and Ig (H) titers were determined by endpoint 
titration on plates coated with disrupted viral particles. Titers are shown as the 
reciprocal of the highest serum dilution scored as positive relative to naïve control 


















Figure 3.4. HA (A) and NP (B) - specific Abs and avidity of HA- specific Abs (C) in DR1 
and B10 mice following NC infection. The concentrations were determined based on a 
standard curve using mouse Ig’s. Avidity index was calculated as a ratio of 
concentration of Abs in the presence of NaSCN to the concentration of Abs in the 
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Figure 3.5. The virus-specific ASC response in DR1 and B10 mice following infection 
with different viruses that replicate in the lung. DR1 (A-C) and B10 (D-F) mice were 
infected intranasally with the influenza viruses PR8 (A and D) and X31 (B and E), and 
with the non-influenza virus MHV68 (C and F). Virus-specific ASC frequencies in the 
MedLN were determined by ELISPOT assay at intervals after infection. The ASC 
frequency is shown as a proportion of nucleated cells. The mean + SE is shown for 3-8 















Figure 3.6. Strong germinal center B cell response to NC or PR8 infection in DR1 mice. 
A-E, MedLN cells from DR1 and B10 mice on day 8 after intranasal PR8 infection were 
analyzed by flow cytometry by gating on B220+ cells, followed by PNA+FAS+ gating. 
Representative staining for germinal center B cells is shown in uninfected mice (A) and 
on day 8 after NC (B) or PR8 (C) infection. Staining is shown as 5% contour plots, with 
the number indicating the cell frequency in the depicted gate. Mean frequencies of 
germinal center B cells following NC or PR8 infection are compiled in D and E, 














Figure 3.7. Cytokine secretion by influenza-specific CD4 T cells in DR1 mice following 
NC infection. Enriched CD4+ T cells from MLN were cultured in vitro with APCs and a 
range of class-II restricted peptide epitopes. Cytokine production was determined by 












Figure 3.8. Cytokine secretion by influenza-specific CD4 T cells in B10 mice following 
NC infection. Enriched CD4+ T cells from MLN were cultured in vitro with APCs and a 
range of class-II restricted peptide epitopes. Cytokine production was determined by 








Figure 3.9. Cytokine secretion by influenza-specific CD4 T cells in DR1 mice following 
PR8 infection. Enriched CD4+ T cells from MLN were cultured in vitro with APCs and a 
range of class-II restricted peptide epitopes. Cytokine production was determined by 












Figure 3.10. Cytokine secretion by influenza-specific CD4 T cells in B10 mice following 
PR8 infection. Enriched CD4+ T cells from MLN were cultured in vitro with APCs and a 
range of class-II restricted peptide epitopes. Cytokine production was determined by 










Figure 3.11. The NC-specific B cell response in DR1 mice is modulated by concurrent 
infection with MHV68. DR1 and B10 mice were infected intranasally with NC only, or 
with NC and MHV68. ASC frequencies in the MedLN were determined by ELISPOT 
assay on day 8 (A and B) and day 10 (C and D) after infection. ASCs specific for NC or 
MHV68 were detected using plates coated with disrupted NC (A and C) and disrupted 
MHV68 (B and D), respectively. ASC frequencies are shown as a proportion of 
nucleated cells. E and F, NC-specific serum IgG (E) and Ig (F) levels. Titers were 
determined by ELISA and are shown as the reciprocal of the highest serum dilution 
scored as positive relative to naïve control serum. The mean + SE is shown for 6-9 
















































Innate and adaptive immune mechanisms in the RT play a major role in virus 
clearance. Generation of virus-specific IgA at mucosal surfaces is important for effective 
neutralization of viruses at mucosal surfaces, blocking infection and transmission. In 
addition, establishment of B cell memory, in terms of localization of IgG and IgA ASCs 
in the upper and lower RT, along with effective generation of BMem frequencies is 
important. Although several studies have highlighted the regulation of IgA class 
switching in the gut, currently, it is unclear what mechanisms (similar or different) 
regulate induction of IgA response in the RT. In addition, trafficking mechanisms of 
ASCs and BMem to the upper and lower RT over long-term post infection is not clear. 
More specifically, are there differential factors regulating IgG Vs IgA ASCs trafficking to 
the upper Vs lower RT? Most importantly, how are these features modulated following 
virus infection? The studies described in Chapter 2 provide insight into these aspects. 
The interplay between CD4+ T cells and B cells lead to the generation of high-affinity 
neutralizing Abs and regulating isotype-switch mechanisms. In addition, the cognate 
interaction between these cells also regulates B cell differentiation towards germinal 
center pathway (high affinity) or extrafollicular pathway (rapid, low-affinity). What factors 
regulate these pathways; especially in the context of virus infection in the RT is currently 
not clear. These aspects are addressed in the chapter 3 of the current dissertation, 
along with CD4+ T cell mediated regulation of B cell isotype class switching and 
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